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ABSTRACT
TGPTTG FOR OVARIAN CANCER TREATMENT
Miranda Y. Fong
May 11,2012
This dissertation is a hypothesis-driven research oriented study to determine the role of
the pituitary-tumor transforming gene (PTTG) in ovarian cancer, specifically if it is involved in
neoplastic transformation leading to tumorigenesis through oncogene activation and the
involvement of tumor-suppressor gene, p53. Furthermore, generation of a useful ovarian cancer
mouse model provides a platform technology to screen for ovarian cancer diagnosis and treatment
options.
This dissertation is divided into four chapters covering the etiology of ovarian cancer and
a novel treatment strategy for ovarian cancer. The first chapter reviews the related literature
encompassing the etiology of ovarian cancer, mouse models of ovarian cancer, the biological
function of PTTG, the role of PTTG in cancer and diabetes, and mouse models using PTTG as a
transgene. The second chapter studies the role of PTTG in tumorigenesis in vivo through the
generation ofa PTTG transgenic (TgPTTG) mouse model observed at various ages, ranging from
4 to 10 months. The third chapter is a preliminary study investigating the signaling mechanisms
affected by chemotherapy agent doxorubicin in combination with withaferin A in vitro and in
vivo for the treatment of ovarian cancer. The fourth chapter is a discussion of the utility of ovarian
cancer

mouse

models

and

the

consequences

IV

of the

lack

of a

working

model.
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INTRODUCTION
The ovary is surrounded by a single cell epithelial layer derived from the coelomic
mesothelium during development. The coelomic mesothelium has the potential to undergo
neoplastic transformation to a malignant phenotype and differentiate towards many different cells
types found in the Mullerian tract, including the ovarian stroma, fallopian tube, uterus, and cervix
[2].
The most common form of ovarian cancer is epithelial ovarian cancer (EOC) accounting
for approximately 90% of cases. Other tumor types include germ cell tumors (5%) [3] and sex
cord-stromal cell tumors « 5%) [4]. EOC is further sub-divided into distinct histotypes: serous
(70%), mucinous (5-10%), clear cell (5-10%), and endometrioid (20%) [5]. Furthermore, serous
carcinomas can be divided into high-grade and low-grade lesions, with the former being the most
common [6].
Ovarian cancer is the most lethal malignancy of the female genital tract, being the 5 th
cause of cancer death in women and 8th most common cancer. If ovarian cancer is diagnosed at
Stage I, the five year survival rate is 93.5% but drops to 27.6% at Stage IV where a majority of
cases are diagnosed [7], mainly due to a lack of symptoms and unreliable detection methods.
Current detection methods include transvaginal ultrasound and serum CA-125 levels. However,
with transvaginal ultrasound, ovarian cancer can be mistaken for functional cysts in
premenopausal women, while CA-125 has a high false positive rate [5]. Over the past four
decades, the incidence of ovarian cancer has slightly decreased but the mortality remains
relatively unchanged [7]. This is in part due to a lack of understanding of the etiology of ovarian
cancer and the heterogeneity found across patient tumors, which has made it difficult to produce a
reliable animal model that represents human EOe.

CHAPTER 1

A REVIEW OF THE RELATED LITERATURE
Etiology of Ovarian Cancer

Ovarian cancer can be subdivided into three groups based on tissue of origin. Most cases
are believed to originate from the ovarian surface epithelium (OSE), while stromal cell tumors
and germ cell tumors are relatively rare [8]. However, recently some debate has arisen that serous
ovarian cancer originates in the fallopian tube and migrates to the ovary [9] as tubal ligation
provides a measure of protection against ovarian cancer [ lO]. Despite some progress to define the
mechanism of the etiology of ovarian cancer, the link between normal to neoplastic
transformation has not been clearly established, in part due to a lack of a representative model.
Despite this most animal studies focus on oncogenic activation or tumor repressor gene silencing
to find the switch from normal healthy cells to transformed tumorigenic cells. Several theories
have been suggested: the Gonadotropin Theory, chronic inflammation, and cancer stem cells
(CSCs) all of which will be discussed in detail (Fig. I). Another theory states that the OSE can
invaginate and form inclusion cysts, which can undergo neoplastic transformation either through
stromally-derived growth factors or cytokines that would normally be restricted to the tunica
albuginea [II]. It has also been suggested that incessant ovulation damages the OSE and the
requisite repairs can lead to genetic mutations, as a reduction in ovulation reduces the risk for
developing ovarian cancer from conditions such as oral contraception, pregnancy, and lactation
[2] which ties into inflammation pathways.
The Gonadotropin Theory

Coined by Chinmoy K. Bose [12], the Gonadotropin Theory suggest that constant
excessive exposure to gonadotropins, particularly follicle stimulating hormone (FSH), over-
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stimulate the ovary to cause excessive ovulation resulting in tissue damage. Experiments related
to this theory have provided conflicting results. One study found that FSH reduced the ability of
the surface epithelial cells to proliferate [13] while another study showed that FSH increased cell
proliferation in a cell culture derived from an omental metastasis of epithelial ovarian cancer
(EOC) [14]. To clarify this issue, serum LH and FSH levels were measured in the serum and
cystic fluid of patients with ovarian epithelial neoplasms [IS]. There was a significant difference
between malignant neoplasms and borderline or benign neoplasms. While FSH receptors (FSHR)
are found in 80% of EOC [16, 17], no experiments have been performed to show that FSH can
promote anchorage-independent colony formation to demonstrate cellular transformation in vitro.
Inflammation in cancer

While bacterial and viral agents have been linked to gastric, liver, and cervical cancer
[18, 19], several types of inflammation can promote tumor development, although the mechanism
varies depending on the source of inflammation (reviewed in [20]). With chronic inflammation,
reactive oxygen species (ROS) are produced, which alters the extracellular matrix by altering the
MMP:TIMP ratio and promote metastasis [I !5]. In addition, inflammation is known to promote
cell proliferation, DNA excision and repair, oxidative stress, and a high concentration of
cytokines and prostaglandins [21]. Pelvic inflan1matory disease has also been linked with EOe
development [18]. With tumor-associated inflammation, the tumor microenvironment provides a
niche for immune cells such as tumor-associated macrophages (TAMs), neutrophils, mast cells,
myeloid-derived suppressor cells, and natural killer T cells which have autocrine and paracrine
functions to promote tumor growth through the production of cytokines and chemokines [20].
TAMs are the frequently found immune cell in the tumor microenvironment and may be
necessary for angiogenesis, invasion, and metastasis [22].
Cancer stem cells (C'SC's)

Cancer stem cells (CSCs) are described as "multipotent cells capable of forming
heterogeneous tumors in immunodeficient mice at high efficiency" [23]. Five characteristics are
3
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Figure 1. Comprehensive diagram of the etiology theories of epithelial ovarian
cancer. Adapted from [I].
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used to identify CSCs : I) self-renewal, 2) restriction to a small percentage of the tumor
population, 3) ability to reproduce the heterogenous tumor phenotype, 4) multipotent
differentiation into non-tumorigenic cells, and 5) expression of distinctive cells markers [24-28].
As such, CSCs have also been referred to as cancer-initiating cells [28] or tumor-initiating cells
[24] . The origin of CSCs are thought to come from somatic stem cells that have undergone
mutations transforming them into a cancer phenotype [29], and while evidence has suggested the
presence of ovarian somatic stem cells, their source differs [30, 31]. Others have suggested that
CSCs are fomled from differentiated cells with a cancer phenotype that dedifferentiate into CSCs
[32], a phenomenon that has been seen in cell culture with the epithelio-mesenchymal transition
(EMT) [30], which lends credence to this theory (F ig. 2). CSCs were first identified in acute
myeloid leukemia [33] and have since been identified in many types of solid tumors including
ovarian, breast, prostate, liver, brain, lung, melanoma, colon, and pancreas [26, 28, 34-43] .

Mu ltipotent stem cell

Sel f-renewal

j

Neo-plaslic transfonnation
Differentiatedllineage
restricted cell wilh
cancer phenotype

Cancer tern cell
(C D 133, C 044)
Dedifferentiation

Self·renewal

Heterogenous tumor

Figure 2. Hierarchial model of tumorigenesis from cancer stem cells.
Adapted from [1] .
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In an effort to identify CSCs, two markers have been proposed: C0133 and C044.
i

COI33++ have been found in the EOC cell lines OVCAR-8, while COI33+ . has been found in
the EOC cell lines A2780, PEOI, OVCA432, OVCAR-2, and OV90 [44]. A single C0133' cell
from A2780 or PEO I was only able to produce cells of the same phenotype. In contrast, a single
CO 133+ cell from the same cell lines was able to undergo asymmetric division and produce
C0133+ and C0133' cells. Since a characteristic ofCSCs is to form xenograft tumors, C0133+
and C0133' cells isolated from A2780 were injected into nude mice. C0133+ cells formed larger,
more aggressive tumors with a shorter latency. Immunohistochemistry of the ectopic tumors
showed that the tumors derived from C0133+ cells contained both positive and negative staining,
showing not only self-renewal but capability to produce a heterogeneous phenotype. Tumors
derived from C0133' cells showed none to extremely low staining for C0133. C0133+ cells
have been isolated from primary ovarian carcinomas [45] and represented less than I % of the
total population, a defining characteristic of CSCs.

The C0133+ cells showed anchorage

independent growth by forming colonies in soft agar as indicative of tumorigenic properties and
also had a higher proliferation rate than C0133' cells.

Upon comparing the percentage of

CO 133 + in 8 normal ovaries, 5 benign ovarian tumors, 16 primary ovarian carcinomas, and 25
omental metastases, ovarian carcinomas have a significantly higher percentage than all the other
groups [45].
The other marker C044+ has been identified in human EOC [28, 29, 36, 37, 46]. CSCs
derived from primary stage III serous adenocarcinomas showed anchorage-independent growth,
which clustered into spheres and expressed Oct-4, nestin, Nanog, SCF, Notch-I, and Bmi-I,
suggesting an undifferentiated phenotype, which were able to differentiate into an epithelial
morphology [28].

When the spheroids were injected into nude mice, they were able to

reconstitute the tumor, as hence were designated as CSCs. CD44+/COI17+ cells were highly
tumorigenic and formed heterogenous tumors reconstituting the original tumor phenotype
compared to C044-/COIIT. As few as 100 C044+/COI77+ cells resulted in tumor formation
6

with a shorter latency. CD44+ cells isolated from malignant ovarian ascites samples obtained
from patients with stage IIIIIV ovarian cancer formed spheroids and maintained this phenotype
over 20 passages, suggesting that they have the ability to self-renew [47]. Furthermore, CD44+
cells were injected into nude mice to determine their tumorigenicity.

Purified CD44+ cells

formed tumors that were 10% CD44+ and 90% CD44·, which was representative of the original
tumor phenotype. A differential global gene expression profile of CD44+ cells and CD44- cells
showed that there was difference in genes belonging to families associated with control of cell
death and apoptosis, signal transduction, transcription regulation, and control of cell
differentiation.

In a different study, 19 of 65 clones isolated from the ascite sample of a

malignant grade IV serous adenocarcinoma were immortalized and showed variations in
morphology and growth rates [36]. Of the 19, 10 representative clones were selected and showed
an up-regulation CD44, c-met, epidermal growth factor receptor (EGFR), E-cadherin (9 of 10),
Snail (2 of 10), and Slug. E-cadherin, Snail, and Slug are known mediators of the EMT [48].
Two selected clones underwent transformation, evinced by an increased proliferation rate and
ability to form organized spheroids. These clones also showed the stem cell markers Nestin,
Oct4, and Nanog, which was reduced upon tumor formation in nude mice [36]. Mice given
intraperitoneal injections of EOC cell line SKOV3 formed tumors with a higher proliferation rate
through the interaction of hyaluronan and CD44 to recruit Nanog into the complex, which
functionally coupled to Stat-3 to induce transcription of cell proliferation proteins [46].
Genetic contribution to ovarian cancer

Only about 9% of EOC cases are hereditarily linked to BRCAl or BRCA2 mutations [2].
Part of what makes the etiology of ovarian cancer hard to elucidate is the heterogeneity that exists
between tumor types. For example, ovarian cancer can be sub-classified as serous, mucinous,
endometroid, and clear cell carcinomas depending on histology. Furthermore, the malignancies
can be classified as high-grade or low-grade, each with its own molecular signals. High-grade
tumors grow rapidly without a definite precursor lesion and are relative sensitive to
7

chemotherapy. p53 mutations as well as Akt and Her2 overexpression are more common in highgrade malignancies found in 50-90%, 12-30%, and 20-66% respectively, but are rarely found in
low-grade malignancies [2]. In contrast, low-grade tumors grow more slowly, are relatively
insensitive to chemotherapy, and share molecular characteristic with low-malignant neoplasms
[2]. K-Ras, B-Raf, and PTEN mutations are more commonly found in low-grade neoplasms
found in 30-50% for both K-Ras and B-Raf and 20% for PTEN [2]. Due to stage of the tissue at
collection, it is imperative to differentiate between pathways that initiate and/or contribute to
tumorigenesis from those that trigger metastasis.
Mouse Models of Ovarian Cancer

Animal models have allowed us to study gene contribution to tumorigenesis through
overexpression of potential oncogenes or conditional deletion of tumor suppressor genes. There
have been many different techniques to develop an ovarian tumor model that adequately
represents human ovarian cancer with variable success.
Syngeneic mouse models
Syngeneic models combine in vitro and in vivo methods to generate a tumor model. This
technique was first used in rats by Godwin et al. [49] and Testa et al. [50] on the spontaneous
transformation of surface epithelial cells isolated from rats, a technique which has been used by
numerous investigators for subsequent studies [51-56]. As such, mouse OSE (MOSE) cells are
isolated from the ovaries of virgin wildtype mice and cultured in vitro before transplantation into
recipient mice [57]. Perhaps one of the most revealing MOSE studies was conducted by Roberts
et al. [51], who compared the alterations of the actin cytoskeleton as well as expression of cellular
adhesion proteins versus the number of passages to study the progression of ovarian
carcinogenesis, showing that MOSE cells spontaneously transform with repeated passages. Late
passage cells injected intraperitoneally into immunocompetent C57BL6 mice formed tumors in
numerous organs, showing the transformation from premalignant to highly malignant phenotype
with downregulation of E-cadherin and connexin-43. In another example, Greenaway et al. [52]
8

injected a spontaneously tumorigenic MOSE cell line named ID8 into the ovarian bursal cavity of
C57Bl6 mice. The ID8 cells fonned direct contact with the ovarian stroma, resulting in primary
tumor fonnation, secondary peritoneal carcinomatosis, and extensive ascites fluid production
between 80 to 90 days post-exposure. The cytological and architectural features resembled serous
carcinoma. Interaction between ID8 cells and the ovarian stroma resulted in increased expression
of proliferative and survival markers, including phosphorylated Akt (p-Akt), proliferating cell
nuclear antigen (PCNA), and Bcl-2. Vascular endothelial growth factor (VEGF) levels were also
increased in the serum and ascitic fluid. In conjunction, the pro-apoptotic factor Bax was
decreased. The study supports the theory that the OSE can undergo invaginations and fonn
inclusion cysts capable of undergoing neoplastic transfonnation [11].
ID8 cells have further been used to test the protective effects of a transgene. Transgenic
mice overexpressing apolipoprotein A-I (apoA-I) were intraperitoneally (i.p.) injected with ID8
cells and showed an enhanced survival compared to wildtype animals as the median time of death
in wildtype animals was 86 days vs. 106 days in apoA-I mice. ApoA-I mice also showed
decreased tumor burden whether injected i.p. or subcutaneously [58]
Genetically induced mouse models
One of the first reports to test genetic changes was made by Orsulic et af. [59], who used
an avian retroviral delivery system. Transgenic mice were established to express the TVA virus
receptor making them susceptible to infection to a subgroup of replication-competent avian
leukosis viral-derived vectors (RCAS), thus allowing for the introduction of oncogenes that
would integrate newly reverse-transcribed DNA into the host genome and allow long-tenn
expression. The TV A receptor was placed under control of the keratin 5 promoter to direct
expression to the ovarian epithelium or alternatively under control of the

~-actin

promoter to

direct expression to all cells of the ovary. TVA-transgenic mice were crossbred with p53-1. mice to
generate TV Alp53-!-, which were used to study the oncogenes c-Myc, K-Ras, and Akt individually
and in combination. However, the keratin 5 promoter is constitutively active in the basal layer of
9

stratified and simple epithelia in several organs [60], therefore, it was necessary to isolate the
1

expression of the virally delivered oncogenes. The ovaries were removed from the TV Np53· mice, cultured, and infected in vitro before introduction into recipient mice either by
subcutaneous or i.p. injection or by transplantation under the ovarian bursa. Once infected, the
mammalian cells would not produce detectable levels of infectious viral particles, which limited
1

spreading to the surrounding tissue. Introduction of any two oncogenes in keratin 5-TV Np53- f

ovarian cells was sufficient to drive tumorigenesis. However, p53· • mice develop tumors, usually
lymphomas and sarcomas, at approximately 3 months of age, making cross-breeding cumbersome
as they only produce 1 litter.
Using a novel approach, Connolly et al. [61] targeted simian virus 40 T antigen (SV40
TAg) to the epithelial ovarian surface by using the Mullerian Inhibitory Substance Type II
Receptor (MISIIR) promoter for the production of transgenic animals. While 18 of 36 (50%)
transgenic mice developed bilateral ovarian tumors resembling serous carcinomas by 6 to 13
weeks of age, the aggressiveness of the formation of the tumors inhibited reproduction, making it
extremely difficult to establish a transgenic line via the female founders. One transgenic mice
also developed a uterine mass and while another developed enlarged polycystic kidneys, possibly
due to recombination events during transgenic mouse production. Not unexpectedly, 7 of 25
(28%) transgenic animals developed testicular cancer. Intrapleural invasion of tumors into the
omentum, the mesentery, and visceral and parietal pleura was also observed, possibly due to the
invasiveness of the ovarian tumors. However, SV40 TAg is not known to be a genetic contributor
to ovarian carcinogenesis [2, 62, 63]. Yet despite these limitations, this model has been used for
further experiments by establishing a transgenic line through the male founder [64, 65].
Based off of the MISIIR -SV40TAg transgenic mice, Quinn et al. produced a syngeneic
mouse model of high-grade serous ovarian cancer [66] by removing the ovarian carcinomas from
donor transgenic mice and xenografting them into recipient immunodeficient and wildtype
C57BLl6 mice. The murine ovarian carcinomas cells (MOVCAR) grew only in immunodeficient
10

mice and resulted in consistent SV40 TAg protein production. As p53 is bound to TAg, it results
is p53 stabilization. Similar to MISIIR-SV40TAg transgenic mice, xenografted MOVCAR
resulting is rapid tumor growth with euthanasia necessary within 4-6 weeks as a result of VEGF
expression. In order to develop a more suitable recipient strain, tumor prone MISIIR-SV40T Ag
transgenic mice were subjected to three different surgical manipulations:

I) bilateral

oophorectomy, 2) bilateral oophorectomy and salpingectomy, and 3) bilateral oophorectomy and
salpingectomy with removal of the ovarian bursa. Tumors formation occurred in most mice, with
mice in the third group developing primary peritoneal carcinomatosis of uncertain origin. While
this tumor development made these mice unsuitable as MOVCAR recipients, MISIIR-SV40T Ag
transgenic mice expressing a low amount of TAg are not tumor prone and hence can serve as
immunocompetent syngeneic recipients for MOVCAR.
Models that require either ex vivo manipulation or expression of a transgene during
embryonic development do not accurately represent human EOC, which tends to be spontaneous
in post-menopausal women. In an effort to mimic spontaneous EOC development, FleskenNikitin et al. [67] obtained mice from Anton Berns [68,69] with LoxP sites containing p53 and
Rb alleles to assess gene inactivation in the initiation of EOC. Mice were homozygous for the
mutation and crossbred to generate

oxP
p5JfloxPjl
RbJf oxPjloxp.

'

To assess the efficiency of Cre

recombinase (Cre) expression derived by the cytomegalovirus (CMV) promoter, the ovaries were
removed and cultured prior to exposure to adenovirus infection. Adenoviruses carrying CMVenhanced fluorescent green protein (AdCMvEGFP) were used as a control against adenoviruses
carrying CMV-Cre (AdCMVCre). Administration of AdCMVCre resulted in increased cell
proliferation assessed by BrdU incorporation. To detect the feasibility in targeting the ovarian
bursal cavity in the mouse, AdCMVEGFP was administered. It was detected only in the OSE for
21 days, as expected with a transient adenovirus infection. As a result of both p53 and Rb
inactivation, 33 of 34 mice succumbed to ovarian tumors at a median of 227 days. However,
administration of an adenovirus to achieve the desired results is cumbersome without generating a
II

reproductive line that would spontaneously form tumors. Targeting the ovarian bursal cavity is
difficult at best, making this model not a feasible choice for large-scale applications.
While the previous models developed tumors resembling human serous adenomas,
Dinulescu et al. [70] generated mice that have a transcriptionally silent oncogenic allele of K-Ras

(LSL_K_Ras G12M ) as first developed by Tyler Jacks [71-73], which can be conditionally
expressed through administration of an adenovirus containing Cre. While the LSL_K_Ras G12D +
mice formed benign endometrosis-like lesions and benign lesion within the OSE upon K-Ras
activation, the mice did not form ovarian carcinomas. However, when the LSL_K_RasG1][J,+ mice
were crossed with PTENoxPloxP mice, they developed invasive primary ovarian endometrioid
adenocarcinomas, a subtype ofEOC, suggesting that phosphate and tensin homologue deletion on
chromosome 10 (PTEN) plays a role in tumorigenesis when combined with other oncogenes. This
finding is consistent with PTEN deletion or mutation in other cancer types including
endometrium, breast, thyroid, intestines, prostate, lung, liver, and T-cell lymphomas [74-78].
Concurrent K-Ras and PTEN mutations have also been found in complex endometrial
hyperplasias, the precursor type of uterine endometrioid adenocarcinomas [79]. PTEN and
adenomatous polyposis coli (APC) tumor suppressor genes were similarly conditionally deleted
upon administration of an adenovirus carrying ere to created PTENoxP/loxP mice [80]. APC has
been shown to regulate Wnt/f3-catenin signaling [81]. PTENoxPlloxP mice were cross-bred with
APC,"oxP!loxP

transgenic mice to determine if there was an interaction between the two pathways.

The PTEN·i'APC!' animals developed tumors within 6 weeks upon inactivation, with death
occurring at 19 weeks. These tumors resembled human OEA, with increased signaling through
Akt. Loss of E-cadherin and cytokeratins indicated that these tumors were undergoing epithelialmesenchymal transition (EMT), which is consistent with Wntlf3-catenin and PI3KJAkt activation
[82,83].
Clark-Knowles et al. [84] used BrcalloxPiloxP mice, which upon administration of AdCre
would remove introns 5 through 13 (Brca I L15.13). Conditional deletion of Brca 1 resulted in
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morphological changes, such as surface epithelium hyperplasia and formation of inclusion cysts,
which was not due to increased proliferation. The incidence of these changes increased over time
as observed from 60 days post-infection to 240 days. Interestingly, the genes involved in cancer
initiation and progression p53 [85], E-cadherin [86], and collagen IV [87] were altered in Brcal "'5·
13

ovaries compared to other tumor models. In Brcal "'5·1.1 ovaries, p53 was absent compared to

SV40-induced tumors.

E-cadherin was also downregulated, consistent with pre-neoplastic

transformation. Collagen IV expression was found in the basement membrane, regardless of
morphological changes of the OSE.
More recently, Liang et al. [88] used the MISIIR promoter to drive expression of murine
phosphatidylinositol 3-kinase catalytic subunit plIO-alpha (PIK3CA) in transgenic mice.
Although over-expression of PIK3CA resulted in increased phosphorylated Akt as its
downstream target and in OSE hyperplasia, after 18 months post-birth of the F 1 generation,
tumorigenesis did not occur. Interestingly, the authors cultured isolated ovaries from nontransgenic mice and co-transfected them with both PIK3CA and mutant K-Ras or c-Myc to assess
OSE transformation in vitro. Concurrent overexpression of PIK3CA and mutant K-Ras led to
increased anchorage-independent growth of cultured OSE cells. Liang et al. [88] acknowledged
that producing a "bigenic" animal by crossbreeding the transgenic PIK3CA mouse with a
transgenic mutant K-Ras remains a technical challenge because mutant K-Ras animals develop
tumors that inhibit reproduction. However, they suggested that a Cre-Iox system of K-Ras
expression may provide an alternative method of generation.
A summary of promoters and targeted genes in epithelial ovarian tumorigenesis can be
found in Appendix 1, Table 1.

PTTG Expression and Biological Function
Under normal physiological conditions, the pituitary tumor transforming gene (PTTG) is
robustly expressed in the adult testes and thymus, with weaker expression in the colon, small
intestine, brain, lung, pancreas, placenta, and in the embryonic liver [89-91]. PTTG cDNA has
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been cloned from adult testes and embryonic liver [92, 93]. PTTG earned its name from being
first cloned from rat pituitary tumor cells as a 974bp mRNA that yielded a 199 amino acid
protein, which was not expressed in the normal pituitary [90]. Structural homology identified that
PTTG was identical to human securin [94]. The C-terminal domain of securin binds to the Nterminal domain of separase to inhibit it and thus chromosome separation [94, 95]. Through
immunoprecipation, the N-terminal domain ofPTTG binds to Ku70, the regulatory subunit of the
Hu70:Ku80 heterodimer that composes the DNA-dependent protein kinase (DNA-PK). In the
presence of a double strand bread,

Ku~W

phosphorylates PTTG to release it from the DNA-PK

complex and allows for PTTG to block separase, and thus couple DNA damage repair with the
delay of mitosis [96].
Downstream signaling/transactivation activity

PTTG overexpression induced transcription of p53 by binding to c-myc to activate the
p53 promoter through its c-myc binding domain and leads to the expression of Bax, a pro-

apoptotic protein [97]. Hence in the presence of DNA damage, PTTG induces apoptosis in a p53dependent and -independent manner. Cells can evade apoptosis through the continuous
degradation of PTTG [98]. p53 is a known activator of p21, a cyclin-dependent kinase inhibitor,
to arrest the cell cycle. In the case of PTTG deletion, p53 levels were not altered, but p21
expression increased dramatically through promoter activation in a dose-dependent manner [99].
In PTTG null pituitary tumors and pancreatic p-cell islets, the ARF/p53/p21 pathway is
frequently activated to induce pituitary senescence, in part by induction of p 19 which prevents
p53 degradation by restraining MDM2 [100, 101]. Reports have been conflicting whether PTTG
deletion promotes or prevents apoptosis [99, 100].
PTTG overexpression has been correlated with the promotion of angiogenesis and
metastasis through increased expression and secretion of several growth factors and stimulators,
including basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), and
interleukin 8 (IL-8) [102-104]. PTTG null mice show decreased vascular invasion by reducing
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FGF2, its receptor FGF I, and VEGF and reducing metastases by decreasing cell motility [105],
while PTTG overexpression correlates with increased VEGF and number of blood vessels formed
[106]. An important signaling molecule downstream of VEGF is inhibitor of DNA binding 3
(ID3) transcription factor. ID3 is upregulated by the SH3 binding domain of PTTG via kinase
insert domain receptor (KDR) expression and phosphorylation, leading to MAPK mitogenic
pathway activation and promotion of angiogenesis [107, lOS]. However, PTTG decreases
expression of thrombospondin-l (TSP-l), which associates with the extracellular matrix to
promote angiogenesis, possibly through p53 as it is a positive regulator of TSP-l [108, 109]. In
the case of metastasis, PTTG overexpression increases matrix metalloproteinase-2 (MMP-2)
expression and secretion, resulting in increases in cell migration and invasion to promote
metastasis (110).

Tumorigenic Potential of PTTG and PTTG Transgenic Mice
PTTG in cancer

As PTTG functions as securin, it is not surprising that PTTG has tumorigenic potential,
as missegregation is predicted to be a major cause of genomic instability with drastic
consequences in cancer development [Ill]. Furthermore, PTTG overexpression in a follicular
thyroid cancer cell line correlated with genomic instability [112] and aneuploidy which included
the presence of micronuclei and multiple nuclei in the absence ofp53 [98].
PTTG is overexpressed in a variety of cancers including renal clear cell carcinoma,
ovary, uterine, pituitary, thyroid, lung, colon, liver, and brain [91, 99, 113-1IS]. Interestingly,
PTTG overexpression was detected in several tumor cell lines including promyelocytic leukemia
HL60, cervical adenocarcinoma HeLa cell S3, chronic myelogenous leukemia K562,
lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji, colorectal adenocarcinoma SW480,
lung carcinoma A549, melanoma G36l, multiple hepatoma cell lines (SH-Jl, SK-Hepl, and
Huh7), and multiple astrocytoma cell lines (US7MG, U138MG, and LN405). Although PTTG is
overexpressed in pituitary tumors, a mutational study revealed that PTTG overexpression was not
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due to promoter mutations [119]. PTTG overexpression, either as a result of degradation failure
or enhanced accumulation, has induced aneuploidy in the lung cancer cell line H1299 by
inhibiting mitotic progression and chromosome segregation. Futhermore, PTTG is capable of
inducing transformation in mouse fibroblast NIH3T3 cells when analyzed using anchorageindependent growth shown by forming larger colonies than control cells [91].

When PTTG

overexpressing cells were injected into athymic nude mice, all 5 mice developed tumors within 2
weeks. Mutations in the structure of PTTG resulted in no tumors after 3 weeks of injection [91].
This was followed by a similar study using HEK 293 cells to see if PTTG could induce
transformation in human cells without necessitating a partner oncogene [102]. HEK 293 cells
stably transfected with PTTG (HEK-PTTG) showed increased cell proliferation, whereas
mutations in the proline rich region of the sequence (HEK-mPTTG) did not. Soft agar colony
formation also increased 30% in HEK-PTTG compared to vector only at 2%. HEK-PTTG formed
poorly differentiated tumors upon subcutaneous injection into athymic mice, suggesting that
PTTG is a potent oncogene that does not require co-expression of other oncogenes to achieve its
tumorigenic function. Futhermore, cloning and sequencing of PTTG isolated from tumors shares
the same sequence homology as that isolated from human testes eDNA suggests that it is
overexpression and not mutation that contributes to its oncogenic properties [94].
To explore the role ofPTTG in tumor growth and progression, siRNA against PTTG was
utilized. In the lung cancer cell line H1299 [120], a 60% reduction in PTTG protein resulted in
reduced colony formation in soft agar showing that PTTG suppress tumor growth in vitro.
Untransfected H1299 cells and cells transfected with control siRNA formed tumors upon
injection into nuJnu mice after 2 weeks. Tumor mass at the end of 4 weeks was 232.12±102.78
mg from untransfected cells and 231.57±83.76 mg from control siRNA cells. However, cells
transfected with PTTG siRNA suppressed tumor growth only formed small tumors (67.85±45.87
mg) in 3 out of the 5 animals. No tumor growth was evident from PTTG siRNA cells before 2
weeks. A similar study was carried out using an ovarian cancer cell line A2780 with similar
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results [116]. PTTG deletion resulted in reduced cell proliferation, decreased colony formation in

vitro, and reduced tumor growth and development ;n vivo. In the invasive sarcoma SH-J I
hepatoma cell line, PTTG silencing resulted in reduced cell proliferation and apoptosis in vitro
and reduced tumor formation in vivo [99]. Huh-7 or SH-JI hepatoma cells were injected
subcutaneously into nude mice. Huh-7 cells mock injected with PBS formed large tumors over
2cm2 in 2 weeks while growth was inhibited in Huh-7 PTTG siRNA cells. SH-Jl injected into
nude mice had similar results with I mouse in 7 injected with SH-JI PTTG siRNA cells being
tumor free.

lnpuence on cell proliferation in diabetes and cancer
PTTG null mice were first generated by Wang et af. [121] and showed significant
metabolic changes resulting from reduced pancreatic

~-cell

proliferation with pleiotropic nuclei

leading to decreased insulin production and elevated blood glucose levels ranging between 150 650 mg/dl.

~-cell

mass is controlled through several cellular mechanisms: expansion occurs from

proliferation of existing

~-cells,

increase in

~-cell

cells. Upon further exploration, the pancreatic

size, and neogenesis from ductal progenitor

~-cells

from PTTG null mice showed reduced

proliferation measured by PCNA labeling and increased apoptosis by TUNEL assay [10 1]. PTTG
null males can be rescued from diabetes development by undergoing surgical gonadectomy
followed by estradiol treatment through increased serum adiponectin levels resulting in increased
insulin sensitivity [122]. As a follow-up study, the mechanism of reduced pancreatic

~-cells

proliferation by PTTG deletion was determined [123]. Staining for insulin and the transcription
factor pancreatic duodenal homeobox 1 (PDX-l) as markers for neogenesis were positive in both
WT and PTTG null mice indicating that it is defective replication, not differentiation, that is
responsible for the decreased

~-cells

mass. In order to further study this mechanism, murine

PTTG (mrPTTG) was linked to EGFP (mrPTTG-EGFP) and expression driven using the CMV
promoter. This constructed was transfected into MIN6 cells. Microscopy was utilized to
determine localization of mrPTTG-EGFP at interphase in the nuclei and cytoplasm and at
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anaphase in the cytoplasm only as the nuclear envelop was dissolved. The duration of mitosis was
directly related to level of mrPTTG-EGFP expression: low expression levels doubled the
duration, medium expression levels prolonged mitosis 4- to 5-fold, and high expression levels
blocked mitosis for at least 2 hrs. Cells did not undergo division until all the mrPTTG-EGFP was
degraded. EGFP alone was indistinguishable from untransfected cells. Futhermore, mrPTTGEGFP co-immunoprecipitated with V5-separase. These results indicate that mrPTTG functions as
securin to regulate cell division in pancreatic B-cells. Intracellular insulin levels did not differ
between groups, suggesting that insulin production was not affected by mrPTTG.
l

Rb+ - mice develop pituitary tumors with almost complete penetrance [124, 125]. In order
to investigate whether PTTG deletion could abrogate tumor development, Rb +I-PTTG+- mice
1

were crossbred to obtain Rb+"PTTG- - animals. Rb+i-PTTG-1- animals had lower spleen, pancreas,
testes, and pituitary weights compared to Rb +'-PTTG++ mice. As a result of PTTG deletion, either
genetically or using shRNA, pituitary corticotroph cells displayed decreased cell proliferation due
to an increase in p21 mRNA and protein, and resulted in reduced incidence of tumor development
and increased survival time [126].
Mice with mutations in the thyroid hormone B receptor gene (TRBPViPV) exhibit severe
dysfunction of the pituitary-thyroid axis, impaired weight gains, and abnormal bone development
consistent with the human syndrome resistance to thyroid hormone (RTH). These mice differed
from mice with a null phenotype for TRB [127]. However, when TRBPV/PV mice were crossbred
i
with PTTG- - to create doubly-mutant mice, they displayed decreased thyrocyte proliferation
resulting in decreased thyroid growth and ablation of goiter development as seen with TRB PViPV
mice. TRBPV/pvPTTG/- mice did not have altered pituitary-thyroid dysregultation. While PTTG
deletion did not alter follicular thyroid cancer development in TRB PV/PV mice, there was decreased
vascular invasion trending towards decreased lung metastasis [105].

PTTG transgenic mice
Abbud et al. [128] produced transgenic mIce usmg the common a-subunit of the
glycoprotein hormones promoter, referred to as the a-subunit of glycoprotein hormone (a-GSU)
to drive expression of PTTG and enhanced green fluorescent protein (EGFP) to target expression
to the gonadotrope and thyrotrope cells of the pituitary. Transgenic mice developed enlarged
pituitaries along with increased serum IGF-I and testosterone. Using scanning confocal
microscopy to detect EGFP expression on the surface and IOOflm deep, the authors found that
EGFP-positive cells in transgenic mice were arranged in two bilateral streaks. These streaks were
arranged next to blood vessels. Some of the transgenic animals with focal PTTG expression
showed loss of the reticulin network, indicating microadenoma rather than hyperplasia. However,
the most striking phenotype in transgenic males was urinary tract obstruction secondary to
prostate hyperplasia at 8-12 months of age with enlargement of the seminal vesicle and showed
fibromuscular stromal thickening upon histological examination.
l

As Rb+ were known to develop pituitary tumors, Donangelo et al. [129] crossbred a.

GSU-PTTG-EGFP transgenic mice with Rb+' transgenic mice to develop a bitransgenic animal to
futher understand the role of PTTG in pituitary tumor development. a-GSU-PTTG mice
displayed normal pituitary cells with the exception of gonadotrophs cells, which showed
abundant secretory vesicles and very active Golgi complexes. However, a-GSU-PTTGlRb +1. had
more diverse cell morphology, ranging from minute secretory granules similar to a-GSU-PTTG
pituitaries to massive grandotroph hyperplasia showing several small and large secretory
granules. Glycogen p-particles were also present in cytoplasm. Three a-GSU-PTTG/Rb+!· mice
also developed pituitary tumors. One 5-month old male developed one tumor of gonadotroph
origin and another derived from a thyrotroph cell. Two females (12- and 13-months old)
developed gonadotroph neoplasms. Using confocal microscopy, 88% (192 of 217) of a-GSUPTTG mice expressing EGFP and 95% (97 of 102) of a-GSU-PTTG/Rb+ i • displayed altered
l

nuclei as a result of chromatin reorganization. a-GSU-PTTG/Rb+ . also exhibited large nuclear
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vacuoles. The altered nuclei were compared to wildtype (9%, 19 of 213), mono transgenic Rbi- i (28%, 62 of 222), EGFP negative monotransgenic a-GSU-PTTG (23%, 10 out of 43), and EGFP
negative bitransgenic a-GSU-PTTGlRb +'. (14%, 13 out of 93) animals. The age of tumor
development was not significantly different between Rb i"i- and a-GSU-PTTG/Rb +-. However,
80% (16 out of 20) Rb +/- pituitary tumors originated from the intermediate lobe, 10% (2 out of 20)
from the anterior lobe, and 10% (2 out of 20) from both lobes. In a-GSU-PTTGlRb +i- only 36% (6
out of 20) arose from the intermediate lobe, 25% (5 out of 20) originating from the anterior lobe,
and 45% (9 out of20) from both lobes.
In a previous experiment through our lab, the construct for targeting PTTG to the ovary
epithelium used the promoter reported by Connolly el af. [61], MISIIR, to produce MISIIR-PTTG
transgenic mice [130]. Transgenic ovaries showed an increase in the corpus luteum mass
accompanied by the increase in serum luteinizing hormone (LH) and testosterone levels. The
transgenic females also displayed a generalized hypertrophy of the endometrium. This study
showed that by using the MISIIR promoter, 3 different tissues could be targeted: OSE, granulosa
cells, and pituitary. However, possibly due to the weak expression of PTTG, the animals failed to
generate any visible tumors, as the amount of expression is critical in ectopic tumor progression
[116].
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CHAPTER 2
PTTG TRANSGENIC MICE AS A MODEL FOR OVARIAN CANCER

PTTG can function as an oncogene when overexpressed and trigger ectopic
tumorigenesis in nude mice [91, 94], suggesting that it does not require a partner gene in order to
achieve its tumorigenic potential. As PTTG has also been indentified in ovarian cancer taken
from patients at the time of surgical resectioning [116], we wanted to identify the in vivo
tumorigenic potential of PTTG through the development of a transgenic mouse model that could
faithfully represent spontaneous EOC found in patients through the strong, non-specific
overexpression of PTTG using the CMV promoter.
Materials and Methods

Constme/ion ofCMV-PTTG-EGFP transgene

Human PTTG (PTTG) cDNA was subcloned into the pEGFP-N3 vector at the multiple cloning
site between the CMV promoter and downstream enhanced GFP (EGFP) reporter gene.
Subsequently, the vector was cut using restriction enzymes Ase I and Afl II by incubating each
restriction enzyme individuaIIy with the vector for 2 hrs at 37°C to reduce the transgene size and
eliminate unwanted genes. The first restriction enzyme was neutralized with phenoVchloroform
and DNA was purified before addition of the second restriction enzyme. The restricted vector was
run on a 0.7% agarose gel to isolate the transgene fragment, CMV-PTTG-EGFP (2.3kb; Fig. I).
CMV-PTTG-EGFP was excised from the gel and purified using a gel extraction kit (Qiagen).
CMV -PTTG-GFP was then sent for sequencing to ensure mutation of PTTG had not occurred.
Animal housing

Mice were housed in a conventional facility with a 12 hr light: 12 hr darkness cycle. All animals
were treated in accordance with National Institutes of Health Guidelines for the Care and Use of
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Laboratory Animals and approved by Animal Use and Care Committee at the University of
Louisville.
Generation of transgenic animals

Purified CMV -PTTG-GFP trans gene was sent to the University of Cincinnati, Transgenic Mouse
Core, where microinjection was performed into the male pronucleus ofFVB 0.5 day old embryos.
Embryos were then transplanted into a pseudo-pregnant female to generate founders. Wildtype
males were bred to positive TgPTTG female founders. TgPTTG FJ males were bred to wildtype
females to establish a colony line.
P53+' Mice
l

P5r mice on an FVB background were obtained from Jackson Laboratory.
.

mouse was used to crossbreed with founder 71305

(~).

A male p53+i .

Female p5r' were crossbred with a

transgenic male to create TgPTTG/p5r' mice.
Genotyping and screening of transgenic and p53+' mice

Mice were tail clipped between 21-28 days of age and ear tagged or toe tattooed with an ID
number. DNA from tail clips was extracted using PCR Extract-N-Amp kit (Sigma). hPTTG-GFP
(PTTG t) genotype was identified via PCR using the specific primer: hPTTG 16182: sense 5'ACT GAG AAG ACT GTT AAA GC-3' or hPTTG 16207: sense 5'-ACG AAT TCA TGG CTA
CTC TGA TCT ATG T-3', and GFP antisense 23759: 5'- AGA TGA ACT TCA GGG TCA GC3' that specifically amplified the transgene sequence. PCR conditions were I) 94°C for 5 min, 2)
94°C for 30 sec, 3) 58°C for 30 sec, 4)

noc for 7 min. P53+

t
•

noc for

I min, 5) Steps 2-4 repeated for 30 cycles, 6)

were genotyped via PCR using the specific primers according to Jackson

Laboratory Protocol: Wildtype: sense 5'-ACA GCG TGG TAC CTT AT-3', Common: sense 5'TAT ACT CAG AGC CGG CCT -3' ,and Mutant: 5'-CTA TCA GGA CAT AGC GTT GG-3'.
PCR conditions were I) 94°C for 3 min, 2) 94°C for 30 sec, 3) 64°C for I min, 4)
min, 5) Steps 2-4 repeated for 35 cycles, 6)

noc for 2 min.
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noc for

1.5

RNA isolation and analysis l?{transgene expression via RT-PCR

Total RNA was isolated from tissues by preserving tissue in RNALater (Sigma) at the time of
sacrifice. Tissues were homogenized in I ml Trizol (Sigma) and isolated via standard procedure.
I I1g of total RNA was converted to cDNA using a reverse transcription kit (BioRad). Total
cDNA was then subjected to PCR as described above for PTTG-EGFP expression.
Histological analysis and immunohistochemistry

Tissues samples were fixed in 10% formalin buffer (Fisher Scientific) overnight at RT. After 24
hr formalin was replaced with 70% ethanol and stored at 4°C until processing. Tissues were
imbedded in paraffin using standard technique. Six micrometer sections were stained with H&E
by the Pathology Core Research Laboratory, University of Louisville and evaluated by a licensed
human pathologist, Hanan 1. Farghaly, MD.

For immunohistochemistry, sections were

deparaffinized in fresh xylene and rehydrated in a graded series of ethanol. Antigen retrieval was
conducted by incubating the slides in 10 mM Sodium Citrate (pH 6.0) at 95°C for 20 min then
rinsed twice with PBS. Slides were incubated in 4 drops per section of Image-It FX Signal
Enhancer (Invitrogen) for 30 min with humidity then rinsed with PBS. Slides were blocked with
10% goat serum (Sigma) in PBS for 1 hr followed by anti-PTTG I: 1,500 dilution in PBS and
incubated at 4°C overnight. Slides were then washed in PBS before application of secondary
antibody Alexa 594 anti-rabbit (Invitrogen) I :500 with 1 drop of goat serum per 5 mL and
incubated 45 min at RT in the dark, then washed with PBS. Slides were dehydrated in a graded
series of ethanol, treated with xylene, and mounted with Clarion mount (Sigma). Images were
acquired on Nikon Eclipse E400 and ACT-I.I imaging software (Huntley, IL, USA).
Results

Genera/ion ofCMV-PTTG-EGFP transgenic mice

As a previous attempt to generate PTTG transgenic (T gPTTG) mice did not result in
tumorigenesis, we asked whether the level of PTTG expression was sufficient. To this end we
selected the non-specific strong CMV promoter to drive PTTG expression. Human PTTG
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(PTTG) was subcloned into the N3 expression vector containing the CMV promoter, a multiple
cloning site where PTTG cDNA was inserted, and a downstream enhanced GFP (EGFP) marker
gene (Fig. 3). To test promoter activity, African green monkey kidney fibroblast-like cells
(COS7) were transfected and GFP fluorescence observed with a fluorescent microscope. In order
to reduce the transgene fragment size for ideal transgenic mouse production, the N3 vector was
cut with two restriction enzymes, Ase I and Afl II, that did not impact hP1TG cDNA resulting in

AseI

AtlII

CMV promoter

V40poly Atail

enseprimer(l)

Figure 3. Transgene
constmct made from
cloning vector
N 3EGFP. Total
transgene size is
2.3kb .

Antisense primer (2)

the fragment CMV -PTTG-EGFP (Fig. 3). This purified fragment was also transfected into COS7
cells to determine recombination and then microinjected into the male pronuclei of 0.5 day old
Friend Virus B-Type (FVB) embryos. Transgenic founders were identified by PCR screening of
DNA extracted from the tail cl ip of 34 Fo mice using two different sense primers located in PTTG
and one antisense primers located in EGFP (Fig. 3). This resulted in the identification of 1 male
(#71288) and 3 female TgPTTG founders (#71282, 71305, and 71309; Fig. 4). The founders were

Figure 4. Genotype resul ts for u·ansgenic founders using forward primer fo r
hPITG and reverse primer for GFP . Lane I & 21 = 100 bp ladder. Results
indicate #7 1282 (female), #7 1288 (male), #7 1305 (female), & #71309
(temale) are positive.
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Figul'e S. Offspring genotype results. Lane I & 21 = 100 bp ladder; lane 2 -7
= oft'spring from #71282; lane 8-15 = from #71305 ; lane 16-20, 22-23 = from
#71288; lane 24-33 = from #7 1309 ; lane 34-40 = fro m #71282 .

cross-bred with wildtype FVB mice and resultant FJ offspring were genotyped by PCR (Fig. 5).
All founders were fertile and produced an average litter size (Appendix I, Table 2). However, the
male and I female founder failed to transmit the transgene to their offspring (F I), suggesting that
the transgene did not integrate in the germ line during homologous recombination events during
embryo development. TgPTTG males from a single line (founder #7 1309) were cross-bred to
wildtype females through multiple generations to create Fr F4 to generate a sufficient number to
TgPTTG mice. Transgenic males were often aggressive by 6 months of age and had to be
maintained in separate cages. All mice demonstrated hyperactivity during housing.
PTTG expression in CMV-PTTG-EGFP mice
TgPTTG mice were sacrificed at 4, 6, 8, 10, and 12 months of age along with the agematched controls and tissue harvested for RNA isolation and immunohistochemistry. Tissue
distribution was determined by promoter expression [131] and examined by reverse transcription
PCR of RNA samples isolated from the ovary, fallopian tube, uterus, testes, seminal vesicle, lung,
liver, spleen, kidney , and pituitary (Fig. 6). As expected, PTTG expression was detected in all of
the tissues with the exception of the pituitary. The strongest expression was seen in the testes,
with weaker expression in the remaining tissues.
Specificity of the PTTG antibody to PTTG vs. murine PTTG has been addressed [130] .
Immunohistochemistry of the ovary, fallopian tube, uterus, and seminal vesicle showed staining
in the epithelium, while the testes PTTG expression was locali zed to the seminiferous tubules
(Fig. 7) in 4 months old animals.
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Figu"e 6. Reverse-transcription PCR of pecified tissues fro m WT (W) and transgenic (1) mice. Lane I is
ladder, lane 2 is empty, lanes 3-end are samples. B = blank negati ve control of reaction mix without
template. IT = fallopian tube, SV = seminal vesicle.

Histology of CMV-hPTTG-EGFP transgenic animal tissues
Formalin-fixed paraffm imbedded tissues were sectioned and stained with hematoxylin
and counterstained with eosin (H&E). Evaluation of the histology was performed by a licensed
pathologist. Tissues were selected based on CMV promoter expression [131] and was as
additional tissues of interest including ovary, fallopian tube, uterus, and pituitary. While all
tissues were normal in 4 months old TgPTTG mice, pre-cancer conditions (4 out of 15, 27%) and
carcinomas (2 out of 15, 13.3%) were observed as early as 8 months of age. A total of 15 females
and 9 males were included in the transgenic 8 months old group and were compared to 11
wildtype

age-matched

controls.

PTTG-EGFP

expressIon

was

confirmed

usmg

immunofluorescence (Fig. 8). Pronounced follicular cysts and corpus luteum were observed in 6
out of 15 (40%) of TgPTTG females. Pre-cancer conditions included one female (#31) developed
a leiomyoma (Fig. 9a) with chronic inflammation (Fig. 9b). A second female (#286) had
squamous dysplasia with extensive keratinization at the transformation zone between the uterus
and the cervix (Fig. 10), while a third female (#436) developed low grade dysplasia with acute
cervicitis (Fig. 10). PCNA analysis was perfomled to verify hyperplasic conditions. TgPTTG
#286 revealed 25% positive cells with reverse maturation of the squamous epithelium of the
cervix, while TgPTTG #436 was 5-10% positive, localizing to the basal cells and also showed a
pattern of reverse maturation (Fig. 10). These were compared to WT 8 month old cervix (Fig. 10).
Negative controls with no primary antibody were included in the analysis. An additional female
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Figure 7. PTTG-EGFP protein expression in tissues from 4 months TgPTTG mice.
Tissues were formalin -fixed paraffm-embedded and sections cut at 5~m. Sections
were then incubated with PTTG primary antibody and visualized with Alexa 594
secondary antibody (red, column I). EGFP expression was visualized using the
FITC filter (column 2). Column 3 shows the merging of column I and 2.
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(#365) developed hyperplasia of the fallopian tube with endothelial atypia (Fig. 10). PCNA
analysis of #365 fallopian tube was compared to WT fallopian tube and showed 25% positive
cells that were localized to the epithelial glands (Fig. 10). Three females (#269, 366, and 368;
20%) had adenomyosis of the uterus. Two females (13.3%) developed ovarian cancer (Fig. 10).
We decided to use the plus rating system for CD31 staining, where I + means < 25% of tissues
was stained, 2+ means 25-75% of tissue was stained, and 3+ means> 75% of tissue was stained.
TgPTTG #434 developed ovarian serous adenocarcinoma with PCNA staining showed 35%
positivity and CD31 was 2+ (Fig. 11). TgPTTG #436 developed a granulosa tumor and a
follicular cyst with mitotic figures. In this female, PCNA staining was 5% and CD31 2+ (Fig.
II). Comparatively, age-matched WT animals showed 1% PCNA staining of the ovary, which

was localized to the granulosa cells of the follicle as would be expected, while CD31 was 1+ (Fig.
II).

TgPTTG 10 month old group included 10 females and was compared to l3 WT agematched controls. PTTG-EGFP expression was confirmed by immunofluorescence (Fig. 12). One
female developed a pre-cancerous serous cyst adenoma of the ovary. Another developed serous
adenocarcinoma of the ovary and fallopian tube (#381, Fig. 13), while an additional female
developed a tumor of ovarian follicular cells (#383, Fig. 13). PCNA staining was 5-10% in both
TgPTTG ovaries and 15% in age-matched WT controls which was localized to the follicles (Fig.
13). CD31 was similar between WT ovaries and TgPTTG ovaries (I +, Fig. 13). Interestingly,
PTTG expression was higher in the female that developed serous adenocarcinoma vs. the female
with the follicular cells tumor (Fig. 12). Additionally, lout of 20 (5%) developed an ectopic
tumors diagnosed as a papillary serous adenocarcinoma that was 75% positive for PCNA and had
significant (3+) angiogenesis (Fig. 13). Two other females (20%) showed atypia of epithelial cells
of the fallopian tube.
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TgPTTG 12 months old group included II females and 10 males, which was compared to
20 wildtype age-matched controls. One female (#185) developed a papillary serous carcinoma of
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Figure 9. a) H&E taining of leiomyoma found on sternum of
8 months old T gPTTG female #31 , lOX power. b) H&E
staining of nodule found in omentum showing chronic
inflammation. lOX Dower.

Group assignments along with a summary of resu lts can be found in appendix 1, Table 3.
Transgene copy number was assessed to analyze differences between TgPTTG that
developed cancer and those that did not. A standard curve was generated using the N3 vector
containing PTTG (Fig. l4a) using real -time PCR. By calculating the kb size of the vector, a copy
number could be assessed to the standard curve. Then by taking 100 ng of genomic DNA isolated
for the tail clip, the gene copy number was extrapolated from the standard curve (Fig. 14b) as 100
ng of DNA was reported to yield 1.67 x 104 diploid cells [132]. We found no difference in
transgene copy number between TgPTTG mice that developed cancer and those that did not.
Crossbreeding of TgPTTG with p53 +/' mice and histology

P53 mutant (p53 Il1ut) mice were produced by a targeted neo cassette insertion into the p53
locus in the laboratory of Dr. Tyler Jacks at the laboratory of Dr. Tyler Jacks at the Center for
Cancer Research at the Center for Cancer Research at the Massachusetts Institute of Technology
[133] and are available through the Jackson Laboratory. These mice have an 18% incidence of
adenocarcinomas and a 56% incidence of sarcomas [134]. Based on the 56 mice observed (45
p53 +/' and 11 p53 -1·, appendix 1, Table 4), four p53 +" mice (8.9%) developed sarcomas at between
3 and II months, while nine p53'/' (8\.8 %) develop lymphoma and sarcomas between 9 and 12
weeks.
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Figure 10. Immunohistochemistry ofTgPTTG 8 month old
mice with pre-cancer conditions compared to age-matched
WT mice. peNA antibody was incubated overnight then
visualized with DAB (brown color).
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Figure 11. Immunohistochemistry of8 months TgPTIG mice with cancer
compared to age-matched WT mice. PCNA and CD3! antibody was
incubated overnight then visualized with DAB (brown color).

Due to the short lifespan of pS3 -1- mice, pS3+1- mice were chosen for crossbreeding to
increase the incidence, decrease the onset time, and/or possibly change the type of cancer in
TgPTTG mice. Two male TgPTTG mice from line #71309 were crossbred to pS3+1- females to
maximize offspring, resulting in generation F2 (Fig. IS) . PTTG-EGFP expression was analyzed
by immunofluorescence to determine the level of expression (Fig. 16). One TgPTTG/pS3-1- mouse
developed two teratocarcinomas at 7 weeks of age, while another developed lymphoma and
sarcomas at 12 weeks of age (Fig. 17). One TgPTTG/pS3+1- mouse developed adenocarcinoma of
the fallopian tube and sarcomas at 7 months of age (Fig. 17). Group assignments along with a
summary of results can be found in appendix I , Table S.
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Figure 12. Immunofluorescence of TgPTTG 10
months old mice for PTTG-EGFP protein
expression, PTTG antibody was conjugated with
Alexa 594 fluorescent antibody (red), Images
were acquired using confocal microscopy, WT =
wildtype, FT = fallopian tube, AdC =
adenocarcinoma,
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Figure 13. Immunohistochemistry of 10 month TgPTTG mice with
cancer compared to age-matched WT mice. PCNA and CD31
antibody was incubated overnight then visualized with DAB (brown
color). FT = fallopian tube, AdC = adenocarcinoma .
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TgPTTGp53 +1· mICe aged to 8 months included 9 females and 8 males. Of the

TgPTTGp53+1. females aged to 8 months, 4 of 9 (44%) had severe dysplasia of the cervix
resulting in carcinomas in situ along with I of 17 (6%) developing a sarcoma. PCNA showed
intense staining in all sarcomas, congruent with the highly aggressive nature of this tumor type
(Fig. 14). All sarcomas had microvessel formation determined by CD31 (Fig. 17).

TgPTTGp53+1. mice aged to 10 months included 8 females and 6 males. 5 of 8 (63 %)
fema les showed focal to severe cervical dysplasia resulting in carcinomas in situ (Fig. 17), and 3
of 8 (38%) showed dilation of the fallopian tube. 2 of 14 (14%) developed high grade
1

leiomyosarcomas (Fig. 17). Comparatively, p53 +. mice developed sarcomas between 11 - 12
months of age (2 of28, 7%).
The timeline of tumor development in p53 mu1 and TgPTTG/p53 mu1 mice is summarized in
Fig. 18.
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Figure 14. Transgene copy number analysis of TgPTTG mice that developed cancer
and TgPTTG mice that did not. a) Standard curve generated from N3 cloning vector
containing PTTG in the multiple cloning site. b) Real-time PCR analysis of transgene
copy number extrapolated from standard curve plotted as average ± SD. TgPTTG mice
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a)

b)

Figure 15. Sample genotype of
crossbred mice. a) p53
genotype, 400 bp = WT allele
(+), 600 bp = mutant allele (-).
b) PTTG-EGFP genotype.
Lane 1 = ladder, lane 2 =
empty, lane 3 - 11 = sample
DNA, lane 12 = negative
control of master mix wi thout
template, and lane 13 =
positive control.

Discussion
Ovarian cancer is a heterogeneous disease that is classified based on its tissue of origin: epithelial
cells (90%), sex-cord stromal cells, and germ cells [135]. Epithelial ovarian cancer (EOC) can be
further sub-classified as serous (70%), endometriod (20%), mucinous (5-10%), and clear cell (5 10%) [5]. However, the most common type of ovarian cancer, high grade serous, often display
p53 mutations [136]. Gene associated with spontaneous EOC are classified in 4 groups: 1) sex
steroid hormone pathway genes, 2) cell cycle genes, 3) DNA repair genes, and 4) oncogenes and
onco-suppressor genes [137]. Mutations of K-Ras , B-Raf, and PTEN have been reported in
mucinous, endometrioid, and low grade serous. Additionally, approximately 10% of ovarian
cancer cases have been linked to hereditary alteration of BRCAJ or BRCA2 [138] , however, a
majority of cases are sporadic in origin [135].
The pathogenesis of ovarian cancer has been unclear, not only genetic alterations but also
concerning its site of origin. Traditionally, the epithelial cells of the ovary were thought to be the
primary site of origin for high grade serous adenocarcinomas but recent studies suggest that these
tumors may arise from fallopian tube fimbria or fallopian tube -peritoneal junction and
subsequently metastasize to the ovary as ovarian adenocarcinomas, fallopian tube carcinomas,
and peritoneal carcinomas are all embryonically derived from MUllerian ducts [139-142]. In our
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Figure 16. Immunofluorescence of TgPTTG/p53+1- mice for PTTGEGFP protein expression . PTTG antibody was conjugated with Alexa
594 fluorescent antibody (red). Images were acquired using confocal
microscopy. FT = fallopian tube.
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Magnification at 20X.
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TgPTTG model, we observed animals with ovarian adenocarcinomas without fallopian tube
adenocarcinomas. Furthermore, we noted animals that developed adenomyosis of the uterus,
l

suggesting the ovary was the site of origin. However, in TgPTTG/pSr - mice we noted a female
that developed fallopian tube adenocarcinoma without an ovarian precursor lesion.
PTTG is an oncogene involved in pituitary carcinogenesis [lIS] and is overexpressed in
ovarian cancer [116]. In a previous attempt to generate an ovarian cancer model representative of
EOC, PTTG was placed under the control ofMISIIR in an effort to target it to the ovarian surface
epithelium [130]. However, despite PTTG expression in the ovary and testes, these animals
developed cystic glandular hyperplasia but failed to develop ovarian adenocarcinomas. However,
abnormalities in the ovarian structure occurred resulting in an enlarged corpus luteum and
corresponding hormone serum levels. This was possibly due to the weak promoter strength as the
level ofPTTG protein expression was crucial for tumor development [116]. Low levels of PTTG
in the pituitary have been shown to cause senescence [100] rather than increase cell proliferation
as seen in PTTG transfection ofHEK 293 cells [102].
Due to the lack of specific ovarian promoter, we selected a strong non-specific CMV
promoter, to induce the necessary level of PTTG to achieve this biological function, as the level
of PTTG is critical for tumorigenesis [116, 120] . However, due to the nature of this promoter, it
was necessary to analyze other tissues to determine if tumorigenesis has occurred. We found that
the CMV promoter seems to target the ovary and fallopian tube and that PTTG expression caused
the development of carcinomas. By using this approach, we were able to generate ovarian tumors
as early as 8 months of age (Fig. 9) and continued to observe them at 10 months (Fig. 11).
However, since our incidence of ovarian cancer was -20%, we cross-bred our TgPTTG mice with
pS3+- mice. Using this approach resulted in earlier tumor development than PTTG or pS3+'- alone
1

(Fig. 18) and increased our incidence of high grade leiomyosarcomas from 7% in pS3+ - mice to
14% in TgPTTG/pS3+ 1-. We also noted a significant incidence of cervical carcinomas of 63% in
TgPTTG/pS3+!-. Most cases of cervical cancer in women are due to human papilloma virus (HPV)
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infections that cause inactivation of p53 and Rb, mutations that mainly affect the squamous
epithelium along the transfomlation zone as HPV infections require cells that are proliferating
(19]. In our TgPTTG mice, we noticed a reverse maturation of the basal squamous epithelium
coupled to dysplasia. As PTTG increases cell proliferation as observed by PCNA staining, PTTG
could serve to prime the basal epithelium, which could make these particular cells more
susceptible to further neoplastic transformation due to alterations of additional genes, such as
p53. We also noted a teratocarcinoma in TgPTTG/p53+

i
••

While little is known about the genetic

contributions to teratocarcinomas, the field theory states that normal germ cells that are placed in
an environment that allows expression of the cancer phenotype have the potential to become
cancerous (143].
P53 has been shown to be an important oncogene in ovarian carcinomas. It is frequently
mutated in 50-70% of ovarian carcinomas [144]. In combination with two other oncogenes cr

f

Myc, K-Ras, and Akt, p5T - mice developed ovarian tumors [59]. Contact mutant p53+ - mice

cross-bred with K-Ras transgenic mice showed that contact mutant p53 +1- acted in a dominantnegative fashion to promote K-Ras initiated lung adenocarcinomas with a subset developing
sinonasal adenocarcinomas [145]. This was also the case in a p53+i -IK-Ras model of pancreatic
cancer [146, 147] and pleomorphic rhabdomyosarcoma [148].
In conclusion, we show that PTTG is a functional oncogene that is capable of initiating
transformation of normal tissue to dysplastic. Furthermore, a high expression level of PTTG was
capable of tumorigenesis in the ovary and lead to tumorigenesis of the fallopian tube. Coupling
PTTG overexpression with mutation of p53 led us to conclude that the early neoplastic events
(normal to dysplastic) were independent of p53 as the additional mutation did not enhance our
incidence of ovarian cancer. This suggests that p53 may not be the correct partner for PTTG, and
further studies involving other potential oncogenes (K-Ras, B-Raf, c-Myc) and tumor suppressor
genes (PTEN) in combination with PTTG may provide a better understanding of the
transformation and tumorigenesis of ovarian cancer.
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CHAPTER 3
WITHAFERIN A ENHANCES THE THERAPEUTIC EFFECT OF DOXORUBICIN
THROUGH ROS-MEDIATED AUTOPHAGY IN OVARIAN CANCER CELLS
It is estimated that $4.4 billion is spent annually in the US for the treatment of ovarian

cancer [149]. While the mainline treatment of ovarian cancer is cytoreductive surgery followed
by platinum-based chemotherapy (namely carboplatin and paclitaxel) [150-153], most patients
relapse after achieving a complete response [154,155]. If the relapse occurs less than 6 months
after initial treatment, the carcinomas are considered platinum-resistant as is common in relapse,
which accounts for approximately 70% of patients [155]. Due to the poor survival of women with
platinum-resistant ovarian carcinomas, an alternative treatment strategy is desperately needed.
Doxorubicin (Dox) is a broad-spectrum anthracylin isolated from Streptomyces peucetius
that has been used for the treatment of several cancers, including ovarian, breast, and prostate
[156]. In fact, anthracylins are the most widely used USDA approved anticancer drugs [157].
Doxorubicin's effectiveness has been attributed to its ability to intercalate between the DNA
strands to act as a topoisomerase II inhibitor and/or bind covalently to proteins involved in DNA
replication and transcription [157]. However, despite side effects, patients treated with pegylated
liposomal Dox (commercially known as Doxil) have a greater response rate (28.3%) than more
conventional therapies [155] during clinical trials in the second-line setting [158-160]. Moreover,
patients treated with Doxil have a reduction in death compared to patients on topotecan [159] or
paclitaxel [161]. As such it remains a standard treatment option in patients that have platinumresistant and recurrent ovarian cancer [162]. In a phase I clinical trial of 30 patients, Doxil was
combined with bevacizumab in patients with recurrent or refractory ovarian cancer. Patients
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achieved an overall response rate of 33% and a 6-months progression free survival of 47% with
no treatment related deaths [162]. Additionally, in a multicenter phase III clinical trial of 976
patients with recurrent ovarian cancer, combination of Doxil with carboplatin vs. paclitaxel with
carboplatin was statistically superior resulting in reduced severe nonhematologic toxicity, 28.4%
vs. 36.8% respectively [161].
More recently combination therapy with Dox has garnered more attention. Combining
Dox with sildenafil resulted in enhanced cell death through the down regulation of Bcl-2 coupled
to an increase in caspase 3 and enhanced the Dox-induced generation of reactive oxygen species
(ROS) while attenuating Dox-induced cardiac dysfunction [163]. Dox has also been combined
with HO-3867, a synthetic curcumin analog, to achieve enhanced cell death and reduced
cardiotoxicity through the use of lower doses of Dox [164]. Interestingly chebulagic acid, a COX-

2/5-LOX dual inhibitor, lead to increased intracellular accumulation of Dox through modulation
of multi-drug resistance transporter I (MDRI) to enhance Dox's cytotoxic effects [165]. MDRI
expression was down regulated in a Cox-2 dependent manner through inactivation of signal
transduction pathways Akt, ERK, JNK, p38, and NF-KB [165]. However, some chemicals when
combined have an antagonistic effect, such as sorafenib and Dox [166]. Dox requires that
Raf/MEKIERK signaling be intact for its mechanism of action to occur [167,168], therefore the
ERK inhibitor sorafenib acts counter to Dox, resulting in increased cell survival and reduced
formation of autophagic vesicles [166].
Withaferin A (WF A) is bioactive steroidal lactone having withanolide skeleton as its
basic structure. WF A is isolated from the plant Wifhania somnijeria, which has been a part of
Indian traditional medicine for centuries and is now available as an over-the-counter dietary
supplement in the US. It was been used to treat various conditions due to its anti-inflammatory
[169, 170] and anti-bacterial properties [171]. More recently, it has been suggested as a potential
anti-cancer compound shown to inhibit tumor growth, angiogenesis, and metastasis [172, 173].
Several biological functions have been influenced by WF A including induction of apoptosis
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through inactivation of Akt and NF-KB [174] as well as decrease of the pro-survival protein Bcl-2
[175, 176], G2/M cell cycle arrest [177], and generation of ROS [178, 179].
Autophagy is a dynamic process that is used to degrade large proteins and organelles,
initiated by environmental stressors resulting in either adaptation and survival, or death [180].
This mode of cell death is characterized by the formation of a double membrane structure that
encloses a portion of the cytoplasm as well as intracellular organelles known as an
auto phagosome [180]. These autophagosomes then fuse with lysosomes (to form an
autolysosome) or late endosomes to degrade the contents [181, 182]. The AktimTOR/p70S6K
signaling pathway acts as one gatekeeper of autophagy that exerts an inhibitory effect by
activating anti-autophagic transcription and translation [183, 184]. DNA damaging agents lead to
inactivation of mTOR evident by dephosphorylation of p70S6K and 4E-BP I [185]. Conversely,
Beclin-l and the class III-type PI3K complex positively regulate autophagy [186].
A previous study has shown at WF A enhances the cytotoxic effect of Dox

In

an

osteogenic sarcoma (U20S) and breast cancer cell line (MCF-7) using a cell proliferation assay
[187]. However, the combined effect of Dox and WF A has not been studied in ovarian cancer.
We proposed that WF A will enhance Dox' s cytotoxic effects so that a suboptimal dose of Dox
can be used to achieve the same effects. We studied the combined effect of Dox and WFA on
epithelial ovarian cancer cell lines A2780, A2780/CP70, and CAOV3. In addition, for the first
time we show that cell death was induced by ROS production and DNA damage leading to the
induction of autophagy and cell death in a caspase 3 dependent manner. We also show the effect
of Dox and WF A on in vitro 3D tumors generated from A2780 cells on a human extracellular
matrix. Furthermore, we examined for the first time the effect of this treatment in vivo on
proliferation, angiogenesis, autophagy, cell death, and DNA damage using xenograft tumors
produced from A2780 cells.
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Materials and Methods
Materials

A2780 and A2780/CP70 cells were cultured in RPMI + 10% FBS + I % Penicillin/Streptomycin

+ 0.05% (v/v) Insulin (Sigma) and maintained at humidified 37°C with 5% CO2 . CAOV3 cells
were cultured in DMEM + 10% FBS + I % Penicillin/Streptomycin. Antibodies to phospho-Akt
Ser473 , Akt, phospho-p70S6K Thr 389 , p70S6K, phospho-BAD Ser 136 , Bel-xL, cleaved caspase 3,
and GAPDH were purchased from Cell Signaling Technology. Ki67 antibody was purchased
from Santa Cruz Biotechnology, CD31 and LC3B from AbCam. Doxorubicin, withaferin A, Nacetyl-L-cysteine, catalase, superoxide dismutase, and DMSO were purchased from Sigma.
Cell treatments

Cells were seeded overnight and treatments were performed in 5% FBS media by adding Dox
(50,100,200,300,500,1000 nM) and/or WFA (0.1, 0.5,1,1.5,2,3,5 f.lM) and/or 0.1% DMSO
as a vehicle controL
Cell proliferation assay
A27~W,

A2780/CP70, and CAOV3 cells were seeded on 96-well plates and treated in triplicates

for 24, 48, and 72 hI. Treatments were then replaced with MTT reagent (Promega) diluted in
fresh 5% FBS media in a 1:5 ratio and incubated -1 hr. Color was assessed by an ELISA scanner
at 492 nM.
Flow cytometryfor Annexin V

Treated A2780 cells were dissociated with versene (Invitrogen), washed in PBS, and the pellet
resuspended in Annexin Binding Buffer to a concentration of I x 106 cells/mL. 2 f.lL of Annexin
V-FITC (BD Biosciences) was incubated for 15 min in the dark in 100 f.lL of cells. Propidium
iodide (PI) was then spiked in and 400

f.lL of Annexin Binding Buffer added and immediately run

on a FACSCaliber (BD Bioscicnces) and analyzed with FlowJo software.
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ROS assay

A2780 cell were seeded on glass bottom 35 mm2 dishes overnight prior to treatment. Treated cells
were loaded with 2 11M 2',T-dichlorodihydrofluorescein diacetate (H 2DCFDA, Invitrogen) in
growth media for 30 min at 37°C. Cells were then washed with PBS and viewed by confocal
microscopy. Cells were counted from 3 representative fields at 20X magnification. ROS
quantification was performed by seeded cells in a 96-well plate in triplicates, counter staining live
cells with lO I1g/mL Hoechst 33342 for lO min for the total cell count, and reading with a multifilter fluorometer.
TUNEL assay

A2780 cells were seeded on chamber slides and treated cells as described for 24 hr. Cells were
then assayed for DNA damage via DeadEnd Fluorometric TUNEL assay (Promega) according to
the manufacturer's protocol. Briefly, cells were fixed with 4% formaldehyde in PBS for 25 min
and permeabilized with 0.2% Triton X-IOO in PBS for 5 min at RT. After equilibration, cells
were incubated with dTd reaction mix for 60 min at 37°C. Reaction was stopped with 2x SSC for
IS min. Cells were counterstained with PI to visualize nuclei.
TUNEL assay in tissue section was performed using an ApopTag Plus Peroxidase
Apoptosis Detection Kit (Millipore) according to manufacturer's protocol.
Protein isolation and Western blotting

A2780 cells were seeded on 6-well plates and treated with Dox (200 nM), WFA (0.5, 1.5, or 2
11M) in RPM! + 5% FBS + 0.5% penicillin/streptomycin + Insulin for 24 hr. Lysis buffer [1%
(v/v) NP-40, 10% (v/v) glycerol, 137 mM NaCl, 20 mM Tris-HCl (pH 7.4), 4 mM PMSF, I mM
NaN04, and 1% (v/v) Triton X-IOO supplemented with proteinase inhibitor cocktail (Sigma) was
added directly to the well and incubated on ice for 10 min then collected into a microcentrifuge
tube and centrifuged at 14,000 rpm for IS min at 4°C and the resulting supernant collected.
Samples were then quantitated using the Bradford method with a BSA standard. Proteins were
resolved with SDS-PAGE and immersion transferred to a nitrocellulose membrane (GE
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Healthcare). Proteins were visualized by ECL or ECL plus (GE Healthcare). Blots were then reprobed with GAPDH to normalize differences in loading.
Xenograft tumor formation

A2780 cells were injected into 5-6 wk old nu/nu mice (Charles River) and tumors allowed to
grow for 20 days until they reached I cm 2 in size. The mice were then randomized into 6 groups:
1) negative control with PBS, 2) control vehicle 10% DMSO, 3) Dox 9 mg/kg, 4) Dox I mglkg,
5) WFA 2 mg/kg, and 6) Dox Imglkg + WFA 2mg/kg. Tumor measurements were taken every
other day and treatments given i.p. in 100

!!L

injections. Mice were sacrificed after 12 days of

treatment. All treatments were approved by IACUC, University of Louisville.
Immunohistochemistry

Xenograft tumors were fixed in 10% neutral buffered formalin and embedded in paraffin for
sectioning. Slides were deparaffinized in xylene and rehydrated in a graded series of ethanol.
Antigen retrieval was conducted by incubating the slides in 10mM Sodium Citrate pH 6.0 for 20
min at 95°C. After washing in PBS, slides were incubated in 0.3% H 20 2 in methanol for 20 min.
Following washing, slides were processed using the Vectastain ABC Elite Anti-Rabbit kit
(Vector Labs) with overnight incubation of the primary antibody. Color was developed using
DAB (Vector Labs) and counterstained with hematoxylin QS (Vector Labs) to stain nuclei.
Primary antibodies used were Ki67 (diluted 1:50, Santa Cruz Biotechnology), CD31 (1:50,
AbCam), LC3B (I :500, AbCam), and caspase 3 (I :200, Cell Signaling).
3D in vitro tumor growth
1.5 x 104 cells were combined with Hubiogel in a 1:4 ratio, dispensed into 10 ilL beads, allowed

to polymerize, and then warm complete media was added to the cells. After two weeks, the cell
beads were individually transferred to one well of a 96-well plate and treated twice weekly with
I) media control, 2) DMSO vehicle control, 3) Dox 0.2 11M, 4) Dox 211M, 5) WFA 0.5 11M, 6)
WF A 1. 5 11M, 7) Dox 0.2 11M + WF A 0.5 11M, and 8) Dox 0.2 11M + WF A 1. 511M for 7 days.
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MTT assay for 3D tumors

MTT assay was performed by adding 20 mL MTT stock solution (12 rnM) to each cell bead in a
96-well plate and incubating for 2 hr until formazan crystals were visible. Then 150 mL of 10%
SDS solution was incubated overnight and read absorbance at 570 nm.
Microscopy of 3D tumors

One cell bead was placed in a 96-well plate and volume corrected to 100 ilL. Calcein AM (0.5
11M) was added to each well and incubated for 30 min. Images were acquired on Nikon B-2E/C
FITC filter block (lex 465-495mn, lem 515-555nm).
Results
WFA enhances the anti-proi(lerative effect oldoxonlbicin of ovarian cancer cells

Dox is typically used at 5 11M to mimic the concentration found in plasma of patients
undergoing Dox treatment [188]. However, at this dose, patients present with serious side effects
as a concentration of I 11M needs to be maintained for the various mechanism of actions to occur
[188]. The effect of Dox alone was first assessed in a dose-dependent manner. Cell death was
assessed by MTT assay. After 24 hr of treatment, Dox alone produced an IC so value of2 11M (Fig.
19a). To assess if WFA could enhance the effect of Dox, we combined a steady dose of WF A
(1.5 11M) with Dox. Combination reduced the IC so to 0.3 11M (Fig. 19a). Dose-dependent WFA
treatment produced an IC so value of3 11M, which was enhanced by the addition of Do x 200 nM to
1.7 11M (Fig. 19b).
To assess the efficacy of combination therapy against cisplatin resistant ovarian cancer,
we used the cisplatin-resistant cell line A2780/CP70. Dox alone produced an IC 50 value of 1.5
11M after 24 hr of treatment (Fig. 19c). Addition of WF A 1.5 11M to Dox further enhanced cell
death and reduced the ICo value to 0.7 11M (Fig. 19c). A2780/CP70 cells were less sensitive to
WF A, requiring 4 11M to achieve 50% cell death (Fig. 19d). Addition of Dox 200 nM enhanced
this effect and resulted in an IC so value of2 11M (Fig. 19d).
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We also tested the effect of combination therapy on p53 mutant cell line CAOV3 as p53
mutations can be found in 50-70% of human ovarian carcinomas [144]. CAOV3 cells were more
sensitive to Dox, since as little as 0.7 I.J.M was able to cause 50% of cell death after 24 hr (Fig.
1ge). CAOV3 cells were also extremely sensitive to WF A as 1.6 I.J.M caused 50% cell death (Fig.
19t). Combination of Dox 200 nM with WF A reduced the IC so value to 1.0 I.J.M.
After 48 hr of treatment of A2780 cells, Dox 0.8 I.J.M produced 50% cell death (Fig. 20a).
Combining a steady dose of WF A 1.5 I.J.M in a dose-dependent manner with Dox enhanced cell
death and reduced the IC so of Do x to 0.161.J.M (Fig. 20a). Dose-dependent concentrations ofWFA
alone resulted in 50% cell death 4.1 I.J.M (Fig. 20b). However, when combined with Dox 200 nM,
the IC so of WF A was reduced to 1.5 !lM (Fig. 20b). In A2780/CP70 cells the IC so value for Dox
was 0.65 I.J.M. However, combination with WFA 1.5 !lM enhanced the IC so of Dox to 0.18 I.J.M
(Fig. 20c). WF A alone required 6 I.J.M to achieve 50% cell death (Fig. 20d), but was reduced to
1.2 I.J.M with the addition of Dox 200 nM (Fig. 20d). CAOV3 cells were more sensitive to Dox
and WF A requiring Dox 300 nM (Fig. 20e) and WF A I I.J.M (Fig. 20t) to achieve 50% inhibition.
When Dox was combined with WFA 1.5 I.J.M, 50% inhibition was achieved with Dox 50 nM (Fig.
20e), while WFA was reduced to 0.7 I.J.M when combined with Dox 200 nM (Fig. 20t). A
summary of IC so values for each cell line in response to Dox, WF A, and in combination can be
found in Table 1.
After 72 hr of treatment, the IC so for Dox in A2780 was 0.4 I.J.M, while addition of WF A
1.5 I.J.M reduced the IC so to 0.1 I.J.M (Fig. 2Ia). WFA 1.7 I.J.M resulted in 50% cells and was

reduced to 1.3 I.J.M with the addition of WF A 1.5 I.J.M (Fig. 21 b). In A2780/CP70, the IC so for Dox
was 0.5 I.J.M, while addition ofWFA 1.5 I.J.M reduced the IC so to 0.35 I.J.M (Fig. 2Ic). WFA 2 I.J.M
resulted in 50% cells and was reduced to 1.3 I.J.M with the addition ofWFA 1.5 I.J.M (Fig. 2Id). In
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CAOV3 , the IC so for Dox was 0.3 ~M (Fig. 21e) and for WFA I ~M, which was reduced to WFA
0.75

~

with the addition of Do x 200 nM (Fig. 21f).
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After 72 hr of treatment, addition of WFA 1.5

~M

=

3.

significantly reduced the cell viability

when combined with various doses of Dox in A2780 (Fig. 2Ia), A2780/CP70 (Fig. 2Ic), and
CAOV3 (Fig. 2Ie). In A2780, Dox 500 nM was necessary to achieve 50% inhibition, but when
Dox was combined with WFA 1.5

~M ,

only 100 nM was needed (Fig. 2Ia) . WFA alone

significantly reduced cell viability in all three cells lines at I

~M

(Fig. 21 b, d, f) . Combination of

Dox 200 nM with WF A significantly improved treatment in A2780/CP70 at nearly all
concentrations ofWFA (Fig. 2Id).
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We performed Annexin V -FITC flow cytometry to determine if apoptosis was the cause
of cell death in A2780 cells treated with Dox and WF A alone and in combination. Positive
control samples were produced using UV exposure for 30 sec and analyzing cells after 4 hr, 6 hr,
and 24 hr after exposure to ensure efficiency of staining (Fig. 22). Analysis of Dox, WF A, and
Dox

+ WF A

treated samples showed a non-significant increase over control for Annexin V (Fig.

23), indicating that an alternative pathway is being used to cause cell death.

Dox enhances the WFA-induced inactivation ofAkt pathway
The effect of WF A on Akt inactivation has been well documented in numerous cell lines
[174, 189, 190] including ovarian cancer cell lines CAOV3 and SKOV3 [191]. Using A2780, we
examined the effect of Dox and WF A alone and in combination on Akt phosphorylation. After
24 hr of treatment, we found phospho_Akt473 (p-Akt) increased with Dox treatment, while there
were no significant changes in WFA treated cells (Fig. 24). Total Akt did not change significantly
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Figure 22. Flow
cytometry for Annexin
V-FITC in UV
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with treatment (F ig. 24). One of the main downstream targets of Akt in mammalian cells is
mammalian target of rapamycin (mTOR), which is responsible for protein synthesis and cell
growth through activation by phosphorylation of p70 ribosomal subunit 6 kinase (p70S6K) [192195]. We found that phospho-p70S6K 389 (p-p70S6K) increased in response to Dox treatment and
more subtly with WF A alone and was further enhanced with combination treatment in a dosedependent manner (Fig. 24). Interestingly, while p-p70S6K markedly increased, total p70S6K
decreased accordingly (Fig. 24).
Akt phosphorylates BAD at Ser l 36 (pBAD I36 ) as a means to regulate apoptosis [196].
While investigating apoptosis in our system, we examined pBAD l 36 as well as Bel-xL. pBAD 136
was only significantly increased in Dox

+ WF A

1.5 11M, while the rest of the treatments did not

alter expression (Fig. 24). Bel-xL levels did not change (Fig. 24), suggesting that intrinsic
apoptosis is not responsible for our observed cell death.
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After 48 hr of treatment WF A led to the inactivation of Akt in a dose -dependent manner
and addition of Dox enhanced this effect (Fig. 24). Total Akt was not affected until Dox was
combined with WF A 2

!J.M

WF A 2

!J.M (Fig.

24). Interestly, we found that Dox 200 nM , WF A 1.5

!J.M, and

alone reduced the total amount of p70S6K which was more pronounced with

combination Dox + WFA 1.5

!J.M (Fig. 24). Combination treatment of Dox + WFA 2 J..lM resulted

in the complete down regulation of p70S6K (Fig. 24). pBAD l36 was significantly downregulated
in all treatment groups with the most drastic effect noticed with Dox alone (Fig. 24) .
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Figure 24. Western blot
analysis of signaling
mechanism after 24 hr of
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quantitated using UNSCAN-IT software and
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normalization with
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ROS-induced cell death
Dox is known to produce ROS as a part of its mechanism [156, 157]. There have also
been numerous reports about WF A generating ROS production as a part of its apoptotic
mechanism in various cancer types [175, 178, 179, 190]. Therefore, we asked whether WFA
could enhance the effect of the low concentration of Dox after 24 hr of treatment using the
detection agent H 2DCFDA, which is a stable non -polar compound that is readily diffused into the
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cells. This compound is then hydrolyzed by intracellular esterases to form DCFH, which in turn is
oxidized by hydrogen peroxide to yield the high ly fluorescent compound 2'7' -dichlorofluorescein
(DCF) [190]. Consistent with reports [163, 197], after 6 hr of treatment WFA 1.5 IlM was
significantly elevated over control cells from 2% to 17% (Fig. 25a-b). Combination of WFA 1.5
I-lM

+ Dox 200 nM further increased ROS production to 59% (Fig. 25a-b). After 24 hr of

treatment Dox 200 nM showed a low level of ROS positive cells, 18% (Fig. 26a-b). While WFA
0.5 IlM (23%) was not significantly different from Dox, combination of Dox

+ WF A 0.5 JlM

increased ROS production to 37%. This effect was even more pronounced with Dox
IlM, which increased to 90% from 40% with WFA 1.5

hr of treatment, WF A 2

+ WF A 1.5

JlM alone (Fig. 26a-b). However, after 24

JlM caused a significant amount of cell death and damaged the cells too

severely to produce ROS.
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Figure 25. ROS production in A2780 cells treated for 6 hr. ROS was detected
with DCF and analyzed by confocal microscopy at 20X. a) Count of DCF
positive cells averaged from 3 fields . * p < 0.05 from control, S p < 0.05 from
Dox, & p < 0.05 from WFA. b) Sample confocal images at 20X.

To confirm that ROS are responsible for cell death, we co-treated A2780 cells with 5 rnM
N-acetyl-L-cysteine (NAC), or with enzymatic inhibitors 500 V/ml catalase or 100 V /ml
superoxide dismutase (SOD) with Dox and WF A treatments for 24 and 48 hr. While NAC did not
block celI death induced by Dox (Fig. 27a-b), it was very effective in blocking cell death induced
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by WFA (Fig. 27c-d) after 24 hr. However, after 48 hr NAC resulted in a partial blockage of Dox
(Fig. 28a-b) while blocking the effect by WF A (Fig. 28c-d). SOD specifically catalyzes
superoxide anions (0 2 -) [198], while catalase is used by cells to degrade hydrogen peroxide
(H 20 2) [199]. We saw no blockade of cell death in cells treated with catalase; however, SOD
provided a significant reduction of cell death in Dox and WF A treated cells in monotherapy and
combination therapy, demonstrating that O2 - are the major ROS produced (Fig. 29a-d).
As ROS causes DNA damage, we performed the TUNEL assay to visualize the extent of
DNA damage when treated with Dox and WF A alone and in combination. After 24 hr of
treatment, Dox 200 nM resulted in a few positive cells while WF A 1.5

~

alone increased the

number of positive cells (Fig. 30). Treatment with Dox 200 nM + WF A 1.5

~

significantly

increased the number of positi ve cells causing DNA damage in nearly every cell (Fig. 30).
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Figure 30. TUNEL assay of
A2780 cells treated for 24hr.
TUNEL positive cells were
labeled with dTd-FITC (green)
and counterstained with PI.
Images were obtained using
confocal microscopy at 20X.
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Dox and WFA induce cell death by autophagy

The Akt/mTORJp70S6 kinase signaling pathway acts as one gatekeeper of autophagy that
exerts an inhibitory effect by activating anti-autophagic transcription and translation [183, 184].
DNA damaging agents lead to inactivation of mTOR evident by dephosphorylation of p70S6K
and 4E-BPI [185]. Therefore investigating the role of chemotherapy agent Dox combined with
WF A in autophagy is an avenue of interest. Electron microscopy revealed control cells treated
with DMSO have intact mitochondria (black arrows) and nuclear envelop (Fig. 29). While WFA
0.5 11M alone had little to no effect, WF A 1.5 and 2 11M showed some autophagosomes but left
the mitochondria intact. Dox alone produce fonnation of autophagosomes containing cytoplasm
with little mitochondria. Dox with WF A 0.5 11M or l.5 11M produced an enhanced effect in a
dose-dependent manner. Dox + WF A 2 11M showed intense autophagic vacuoles, collapse of the
nuclear envelop, and absence of mitochondria (Fig. 31).
To confirm that cells were undergoing autophagy,

the canonical marker of

autophagosome formation microtubule-associated protein-l light chain 3B (LC3B) [166] was
evaluated. Western blot analysis showed two specific bands: an upper band (18 kDa) representing
LC3B-I and a lower band (16 kDa) corresponding to LC3B-II (Fig. 32). Cytosolic LC3B-I is
converted to LC3B-II through lipidation and allows LC3B-II to become associated with
autophagic vesicles [200]. Treatment with Dox induced production of LC3B-II (Fig. 32), while
WF A alone stimulated production of the pre-cursor LC3B-I as well as LC3B-II (Fig. 32).
Combination treatment enhanced LC3B-II in a dose-dependent manner with Dox + WFA 2

!lM

showing the greatest intensity (Fig. 32). Furthermore, we investigated cleaved caspase 3 as a
marker for cell death. Western blot analysis showed a modest increased in Dox 200nM treated
cells. WF A 0.5 11M showed no indication of cell death, while WF A alone showed a dosedependent increase in the amount of cleaved caspase 3. Furthermore, combination treatment
enhanced cell death in a dose dependent manner (Fig. 32).
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Figure 31. Electron microscopy of A2780 cells treated for 24hr showing vacuole
formation upon treatment as an indication of autophagy. Scale bar is 1 /lm. 5,600X power.

60

0
0

200
0

0 200
0.5 0.5

0
1.5

200
1.5

0
2

200
2

Dox

(nM)
(J..lM )

WFA

Fold Change

LC3B-I
LC3B-1I
1
1

1.79

1.41
.59

1.14
0.66

1.82

2.38

Caspase 3

6 .38 6.87

1 .30
GAPDH

Figu r e 32. Western blot analysis of autophagy marker LC3B-II and cell
death marker cleaved caspase 3 in A2780 cells treated with Oox and WF A.
Quantitation was performed using UN-SCAN-IT software. Values were
normalized to GAPOH and fold change calculated by comparing to OMSO
control (0 J..lM).

Effect of Dox + WFA on xenograft tumorigenesis

A2780 cells (2 x 106) were subcutaneously inj ected bilaterally in the ventral flank of 5-6
week old nu/nu mice. Tumors were allowed to grow until they reach 1 cm 2 in size. At day 20
post-cell injection, mice were randomized into 6 treatment groups of 5 mice each: 1) negati ve
control with PBS, 2) vehicle control of 10% OMSO, 3) Dox 9 mg/kg, 4) Oox I mg/kg, 5) WFA 2
mg/kg, and 6) Oox 1 mg/kg + WF A 2 mg/kg. Tumors were measured every other and mice given
100 J..LL i.p treatment for 12 days for a total time of 32 days. Mice receiving Oox 9 mg/kg
appeared uncomfortable after the first treatment and died after 4 treatments . Mice in the other
treatment groups tolerated receiving the treatment. The tumor volume was not significantly
different between vehicle, Oox 1 mg/kg, and WF A 2 mg/kg. However mice receiving Oox 1
mg/kg + WF A 2 mg/kg showed a significant reduction in tumor growth (Fig. 33a). Similarly,
tumor weight measured at day 32 showed a drastic decrease in the Oox 1 mg/kg
group (Fig. 33b).
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Figure 33. a) Xenograft tumor growth of A2780 cells injected into 5-6 week old nu/nu
mice. Treatments were given i.p. every other day. b) Scatter plot distribution of tumor
weight at day 32. Line indicates the mean. Number above group indicates number of sites
that developed a twnor post-treatment vs . total number of sites .

H&E analysis identified the twnors as serous adenocarcinoma (Fig. 34). Vehicle group
tumors were high grade with extensive necrosis. Dox I mg/kg group also had extensive necrosis.
However, WFA 2 mg/kg and Dox I mglkg + WFA 2 mg/kg were poorly differentiated with
tumor necrosis. Immunohistochemistry for Ki67, a proliferation marker, showed intense staining
in the vehicle group with less intense staining in Dox 1 mglkg and WF A 2 mg/kg. Dox 1 mg/kg +
WF A 2 mg/kg showed no staining for Ki67, showing that combination therapy effectively
reduces tumor growth (Fig. 32). Microvessel marker CD3l has also stained. Vehicle control
tumors showed a high amount of microvessel formation , which was reduced in Dox 1 mglkg and
WFA 2 mg/kg. Dox 1 mglkg + WFA 2 mg/kg tumors were no significantly different from Dox or
WFA alone (Fig. 34).
We also performed immunohistochemistry for autophagy marker LC3B. Tumors
receiving vehicle control showed a nest of positive cells whereas tumors receiving Dox 1 mglkg,
WF A 2 mg/kg, or combination showed more dispersed staining (Fig 34). Staining for caspase 3
showed a low level of staining in DMSO and WF A 2 mg/kg treated tumors . Caspase 3 was
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increased in Dox I mg/kg and further enhanced in Dox I mglkg + WF A 2 mglkg treated tumors
(Fig. 34).
TUNEL assay in tumors revealed positive cells in animals receiving Dox I mglkg with a
lower amount in WFA 2 mglkg (Fig. 32). However, combination of Do x Img/kg + WFA 2 mg/kg
showed enhanced staining over monotherapy along (Fig. 34).

E./Ject of Dox + WFA on 3-D tumors in vitro
Hubiogel has been shown to represent the human matrix more accurately than Matrigel
in order to predict preclinical endpoints [20 I]. A2780 cells were cultured to 70-80% confluency
and IS,OOO cells were mixed with Hubiogel in a 1:4 ratio to form 10 I1L beads that were
suspended in warm complete media and given the following doses twice weekly: I) Dox 0.2 11M,
2) Dox 2.0 11M, 3) WFA O.S 11M, 4) WFA 2.0 11M, 5) Dox 0.2 11M + WFA O.S 11M, and 6) Dox
0.2 11M + WFA 211M.

Measurements were taken at day 1, 3, and 7 for MTT assay and

microscopy. Media and DMSO treated cells continued to grow throughout treatment, whereas
Dox 0.2 11M had their growth halted at day 7 (Fig. 3Sa). Dox 2.0 11M and WF A 2.0 11M treated
cells showed reduced tumor growth and showed a more pronounced effect with Dox 0.2 11M +
WFA 2.0 11M (Fig 3Ia). Dox 0.2 11M + WFA O.S 11M achieved a drastically reduced growth
compared to mono therapy of either compound (Fig. 3Sa). Microscopy images from day 3 and day
7 are shown in Fig. 31 c and 31 c respectively.

Discussion
The cytotoxic activity of WF A was been established as an IC so of ~S

!!hl after 72

hr in a

panel of cancer cell lines and transformed fibroblast cell line [202], however this did not include
an ovarian cancer cell line. WF A doses less than SOO nM did not affect cell proliferation [202].
However, in our study we noticed that as little as WF A 300 nM resulted in a noticeable decrease
in cell proliferation in A2780 as well as CAOY3 cells (Fig. 19-21). Consistent with previous
reports on Dox and WFA, we confirm that both agents produce ROS. Combination of Do x +
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Figure 34. Immunohistochemistry of A2780 xenograft tumors. Tumors were fixed in
formalin and paraffin embedded. Primary antibody was incubated overnight and developed
with DAB (brown color). TUNEL was performed with ApopTag Plus Peroxidase
Apoptosis Detection Kit. Images acquired at 20X power.
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WFA further enhanced ROS production (Fig. 25-26). As a result of ROS production, DNA
damage was increase as assessed by TUNEL assay (Fig. 30), resulting in autophagic cell death
(Fig. 31, 32). WFA also reduces in vivo tumor growth of human pancreatic [203] and breast
cancer cells [172]. Here we show a low dose of WF A alone did not affect in vitro or in vivo tumor
growth, however combining a low dose of WF A with a low dose of Dox resulted in significant
inhibition (Fig. 33, 34).
Akt functions as one of the main pro-survival pathways and is frequency dysregulated in
cancer [204]. Furthermore, it has been reportedly over expressed in ovarian carcinomas [205].
Dox has been shown to inactivate of Akl [165]. The effect of WFA on Akt phosphorylation and
apoptosis intrinsic cascade has been well documented. WF A downregulates Notch-l signaling
resulting in the down regulation ofp-Akt and subsequent downstream molecules IKK-a, NF-KB,
p-p70S6 kinase, and 4E-BP in vitro in colon cancer [176]. In ovarian cancer cell lines CAOV3
and SKOV3, WFA resulted in dephosphorylation of Akt in a dose-dependent manner [191]. In
our cell line A2780, we found that after 24 hr treatment with Dox increased pAkt while WFA did
not (Fig 24). This discrepancy could be due to the p53 status of the cells. A2780 cells have WT
p53, while CAOV3 have mutant p53 and SKOV3 are p53-null, which affects expression of
PIK3CA, the gene that codes for the catalytic subunit pll0a of PBK which in tum

phosphorylates Akt [206]. Furthermore, WFA has been shown to directly affect the ability ofNFKB to bind to DNA [174, 2071 and that in tum directly affects transcription of downstream target
molecules such as c-FLIP [179], IL-6, IL-8, MCPl, A20, cyclin D, VEGF, MDR-l, and Bfl-l
[207]. In prostate cancer, NF-KB inhibition was dependent of proapoptotic protein prostate
apoptosis response-4 (Par-4) [208]. Coupled with down regulation of Bcl-2, colon cancer cells
were more sensitive to apoptosis [176]. WFA has also been shown to trigger the intrinsic
apoptosis cascade in melanoma with generation of ROS and down regulation of Bcl-2, showing
that WF A exhibits the properties of two pharmacological agents used in clinical trial (Disulfiram
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and Oblimersen) [175]. In fact, Bcl-2 overexpression in leukemia cells was able to block the
induction of apoptosis induced by WF A, demonstrating that Bcl-2 is important for WF A -induced
apoptosis [189]. In ovarian cancer, we have been unable to detect endogenous amounts of Bcl-2
and perhaps because of the lack of Bcl-2, the action of WF A preferentially uses autophagy rather
than apoptosis to achieve cell death.
Apoptosis was thought to be the principle mechanism by which chemotherapy agents kill
cancer cells. Apoptosis is a highly conserved cellular program that eliminates damaged and
infected cells and consists of two major pathways: the extrinsic pathway that is mediated by death
receptors and the intrinsic pathway that is mediated by the mitochondria. Both pathways lead to
activation of caspases, cysteine proteases that cleave different substrates and cause cellular
breakdown [209]. However, more recent evidence suggests that anticancer agents also induce
other forms of non-apoptotic cell death including necrosis, mitotic catastrophe, autophagy, and
senescence [210-212]. Various anticancer chemotherapies have been shown to induce autophagy
which cooperates with apoptosis to induce cell death [209, 213-216]. Autophagy enables cells to
survive harsh conditions such as chemotherapy treatment and thus conferring resistance [209].
This adaptive response is signified by a high level of autophagy as inhibition of autophagy allows
chemotherapy agents to more effectively kill cancer cells in various cell types exposed to various
drugs [180]. As such, it is still unclear why autophagy participates in cell death is some instances
while preventing it in other, especially since both effects can be observed with the same
anticancer compound. However, autophagy can have tumor suppressive functions. One proposed
pathway suggests that autophagy eliminates damaged organelles that may produce a high level of
ROS and therefore limit chromosomal instability [217]. We found that treatment with Dox +
WF A increased ROS production as early as 6 hr of treatment with continued increase production
with 24 hr of treatment (Fig. 25, 26). This is consistent with previous reports that both Dox and
WFA as a monotherapy both produce ROS [156, 157, 175, 178, 179, 190]. ROS-mediated
autophagy has been observed in a number of different carcinoma cell lines [218-220].
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Additionally, blocking ROS production with ROS scavengers and antioxidants reduced
autophagic cell death is various solid tumors cell lines [220, 221]. Mitochondrial ROS damage
the mitochondrial membrane and result in leakage of ROS to the cytosol where they can damage
other organelles as well as cause DNA damage and oxidation of amino acids and polydesatured
fatty acids [222, 223]. Electron microscopy revealed the presence of autophagic vacuoles which
we confirmed with Western blot analysis of LC3B (Fig. 31, 32). In order to determine the major
pathway of action for Dox + WF A, we analyzed p-Akt levels as well as p70S6K and observed a
decrease of both proteins. Cell death was confirmed with Western blot analysis of caspase 3 (Fig.
32). However, we observed no change in the level of Bcl-xL (Fig. 24) or in Annexin-V flow
cytometry (Fig. 23). Taken together this suggests that cell death is being mediated principally
through autophagy and not apoptosis.
Dox or its derivative Doxil has been used in combination with several other compounds
in various cancer types. Doxil used in combination with bevacizumab in patients with recurrent
ovarian cancer achieved a 33% response rate [162]. In prostate cancer Dox has been combined
with si Ide na fil , which promoted apoptosis through enhancement of the intrinsic pathway
including down regulation of anti-apoptotic proteins Bel-xL and reduced phosphorylation of proapoptotic protein BAD as well as induction of pro-apop to tic protein Bax [163]. This combination
therapy resulted in the generation of reactive oxygen species (ROS), but attenuated the
cardiotoxic action of doxorubicin. Here, we show that Dox alone affected pBAD 136 , an effect that
was attenuated with the addition of WF A (Fig. 24). Chebulagic acid acts synergistically with Dox
by increasing the Dox accumulation intracellularly through down regulation of MDR-I
transporter to enhance its cytotoxicity on hepatocellular carcinoma cell line HepG2 and thereby
decreasing the necessary dosage of Dox to achieve a reduction in cell proliferation [165]. MDR-l
down regulation was achieve through inactivation of signaling pathways Akt, ERK, p38, JNK,
and NF-KB in a COX-2 dependent manner. A synthetic analog of curcumin HO-3867 has also
been used in the same manner to achieve a complementary outcome with Dox to increase cancer

cell toxicity without cardiotoxicity [164]. Using this combination therapy, they were able to
decrease the concentration of Dox from 50llM to 2.51lM to achieve the same anti-proliferative
effect in Dox-resistant breast cancer cell line MCF-7 MDR and showed decreased expression of
Bcl-2 and pAkt. This lowered combination treatment resulted in better cardiac performance in
treated mice. Combining arsenic trioxide with conventional therapies including Dox reduced
cancer stem-like cells in hepatocellular carcinoma cell line and thereby sensitize the carcinoma to
chemotherapy agents [224].
In our study, combination of Dox with WF A resulted in cell death not through apoptosis
(Annexin V, pBAD 136, and BcI-xL), but through ROS-mediated autophagy (p70S6K, LC3B,
caspase 3). We have also demonstrated the efficacy of Dox + WFA for the treatment of ovarian
cancer in vivo using a xenograft tumor model and in vitro using a 3D tumor growth model on a
human extracellular matrix. In both cases, Dox + WF A combination treatment resulted in
inhibited tumor growth. In the case of xenograft tumors, we confirmed this with Ki67 and CD3l
immunohistochemistry .
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CHAPTER 4
CONCLUSIONS

One of the main barriers to developing an ovarian cancer mouse model is the genetic and
epigenetic heterogeneous nature of this disease. At least 17 oncogenes (Appendix I, Table 6), 16
tumor suppressor genes (Appendix I, Table 7), and 7 signaling pathways have been implicated
[225] to be involved in the pathogenesis of ovarian cancer. These pathways include aberrations in
cell proliferation, apoptosis, autophagy, and cell adhesion and motility. Oncogene expression
alterations

utilize

various

mechanisms

including

gene

amplification,

mutation,

and

overexpression, while tumor suppressor gene are mutated or go through loss ofheterozygocity for
silencing protein functionality [144]. In addition, the expression many genes are controlled
through epigenetic alterations such as hypomethylation of DNA, promoter methylation, and
histone modification [144, 225]. Furthermore, micro-RNAs (mi-RNAs) playa role in controlling
RNA stability and thus protein translation, participating in vital pathways including development,
differentiation, cell cycle, apoptosis, metabolism, and proliferation [226]. Similarly to genes, miRNAs can be classified as oncogenes or suppressor genes depending on the pattern of their
alteration. The mi-RNA shown to be overexpressed in ovarian carcinomas are miR-200a, miR141, miR-200c and miR-200b [225]. On the other hand, miR-199a, miR-140, miR-145 and miR125b1 were among the most down-regulated mi-RNAs [225]. With so many genetic alterations
present in a histologically diverse disease, the challenge of developing a spontaneous reliable
model that accurately reflects human EOe becomes immense.
In our transgenic model, TgPTTG, we observed

~20%

incidence of localized ovarian

cancer in 8 month old mice (Fig, 7) and continued to observe them in lO month old mice (Fig. 9)
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as the CMY promoter seemed to target the ovary and fallopian tube. Since our incidence of
i

ovarian cancer was low, we cross-bred our mice with p53+ mice, as p53 is mutated in 50-70% of
-

human ovarian carcinomas [2, 144]. Using this approach resulted in earlier tumor development
than PTTG or p53+!' alone (Fig. 13) and increased our incidence of high grade leiomyosarcomas
from 7% in p53+!- mice to 14% in TgPTTG/p53+!-. We also observed tetratocarcinomas in
PTTG/p53-'- that were not present in p53-1- alone. We also noted a significant incidence of cervical
carcinomas of 63% in TgPTTG/p53+1- at both 8 and lO months, suggesting that this combination
provides an attractive model for studying cervical cancer.
Having a reliable mouse model that accurately reflects the spontaneous human
counterpart would provide a monumental amount of knowledge of the genetic alterations that
occur during tumorigenesis as well as metastasis. In addition, the model would be a useful
method of testing new chemotherapy treatment strategies. But in order for the model to the
reliable, several criteria have been suggested: 1) mice must carry the same mutation that occurs in
human tumors, 2) mutations should be engineered within the endogenous locus, 3) mutated genes
should be silent during embryogenesis and early postnatal development, except in models of
inherited pediatric tumors, 4) mutations should be within the specific target tissues in selected cell
types, and 5) mutations must occur in a limited number of cells [227]. However, the advantage of
using genetically altered mice is the tumor exists in the presence of a competent immune system.
As it stands, it is not surprising that the most used model for testing treatment strategies is the
xenograft tumor model generated in immune compromised nude mice in which human cancer
cells are injected under the skin and form a tumor over time. Xenograft tumors provide a more
accurate tumor response to a patient's response despite the lack of a functional immune system
[227]. However, these human tumors are generated using a mouse extracellular matrix (ECM),
and thus do not accurately reflect patient response. To address this concern, we generated human
3D tumors using human ECM (Hubiogel) to test tumor response to our combination Dox + WF A
therapy. As such, we tested the tumor response to substandard dose of chemotherapy agent Dox
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in combination with WFA to enhance cell death. 3D in vitro and xenograft in vivo tumors
responded to treatment and showed delayed tumor progression when treated with suboptimal
doses of Dox + WFA (Fig. 31, 33). We also demonstrated the mechanism of cell death in
response to Dox and WF A was DNA damage and production of ROS (Fig. 23-27) leading to the
induction of autophagy and leading to cell death in a caspase-3 dependent manner (Fig. 29,30).
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APPENDIX I
Table 1. Summary of promoters and targeted genes in epithelial ovarian cancer transgenic mouse
models. Adapted from [228]. RCAS

=

replication-competent avian leukosis viral-derived vectors,

MISIIR = Mullerian Inhibitory Substance Type II Receptor, AdCre = adenovirus carrying Cre
recombinase, FSHR = follicule stimulating hormone receptor.
Authors

Promoter

Targeted gene

Orsulic et aL (2002)
Connolly et aL (2003)

keratin-5, RCAS
MISIIR

Yes
Yes

Flesken-Nikkita et aL (2003)

AdCre

TVA, p53- -, oncogenes
SV40 TAg
p53-1- & Rh-/-

Dinulescu et al. (2005)

AdCre

K-Ras & PTEW-

Yes
Yes
No

1

Wu et al. (2007)

AdCre

PTEN-- & APC-

Chondankar et al. (2005)

FSHR

Clark-Knowles et al. (2007)
EI-Naggar et al. (2007)
Liang et al. {2(09)

AdCre
MISIIR
MISIIR

Cre, BRCAl-BRCAll>5-J3
PTTG
PIK3CA

Table 2. Breeding summary of TgPTTG founders. WT = wildtype

Founder
71282
71288
71305
71309

Number of
breedings
5 (WT)
5 (WT)
5 (WT)
4 (WT)

Total number of

Number of positive
mice in Fl
None
None
16
19

offs~ring

37
43
42
36
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Tumorigenesis

Yes

No
No
No

Table 3. PTTG transgeruc (TgPTTG) mice group assignments. Number in columns indicate
number of mice assigned to each group.
Age
1 month
3 months
4 months
6 months
8 months
10 months
12 months

Table 4. p53

Female
Control

Male
Control

2
1
4
6

I
1
7
7
10

10

mu,

Female
TgPTTG

Male
TgPTTG

2

2

3

15

3
9

10
11

10
11

TgPTTG
Died
I
1
I
3

1

mice group assignments. Number in columns indicate number of mice assigned

to each group. Genotype of mice as indicated in parentheses next to numbers.
Female p53
Age
9 weeks
2 (-1-)
3 months
4 months
5 months
...----;7:;"'months
~-~~---~~~
8 months
10 months
11 months

mu,

Table 5. Group assignments of TgPTTG/p53

Male J153

0lu,

2 -19 (-1-), 2 (+1-)
1 -1-

mu,

Died

2
11

crossbred mice. Nwnber in columns indicate

number of mice assigned to each group. Genotype of mice as indicated in parentheses next to
numbers.
Age
7 weeks
9 weeks
3 months
4 months
8 months
10 months

Female TgPTTG/p53

mut

Died

8 +16(+1-)
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Table 6. Oncogenes involved in the pathogenesis of ovarian cancer, adapted from [2, 144] with
contributions from [229]. AURKA, aurora kinase A; CCNE1 , cyelin EI ; eEFlA, eukaryotic
elongation factor I-a; EGFR, epidermal growth factor receptor; FGF 1, fibroblast growth factor I;
IGFR, insulin-like growth factor receptor; PIK3CA, PBK catalytic subunit; PRKCI, protein
kinase C.
Oncogene

% Overexpressed

AKTI
AKT2

% Gene
Am(!lification
NA
12-27%

AURKA

10-15%

48%

12-18%
12%

30-50%

B-RAF
CCNEl
eEFIA
EGFRI

11-20%

42-63%
30%
9-28%

ERBB2

6-11 %

4-12%

12-36%

<1%

51%

FGFI
!GFR
K-RAS
MYC
NOTCH3

5%
20%
20-21%

21-25%
30-52%
41-66%
62%

PIK3 CA
PRKC!

9-11 %
44%

32%
78%

RAB25

54%

80-89%

Src

% Mutated

2-24%

8-12%

80-90%

89

Function
Inhibits a 0 tosis
Cytoplasmic serinethreonine rotein kinase
Nuclear serine-threonine
rotein kinase
Promotes growth through
MAPK
C clin
Protein elongation factor
Protein tyrosine kinase
wth factor rece tor
Protein tyrosine kinase
growth factor receptor
Growth factor for cancer and
angiogenesis
Promotes growth
CyjO lasmic GTPase
Transcri tion factor
Cell surface growth factor
rec tor
Cyto lasmic Ii id kinase
Cytoplasmic serinethreonine rotein kinase
Cytoplasmic GTPase and
apical vessel trafficking
Promotes growth,
an io enesis, and survival

Table 7. Tumor suppressor genes dysregulated in ovarian cancer, adapted from [ 144]. ARLl1 ,
ADP-ribosylation factor-like 11; DAB2, disabled homologue 2; DLECl , deleted in lung and
esophageal cancer I ; DSB, double strand break; EGF, epidermal growth factor ; GPI,
glycosy lphosphatidylinositol ; GRB2 , growth factor receptor-bound 2; ILK, integrin-Iinked
kinase ; JNK, JUN N-terminal kinase; LOH, loss of heterozygosi ty; OPCML, opioid-binding
protein/cell adhesion molecule- like; PEG3 , paternally expressed 3; PLAGLl , pleiomorphic
adenoma gene-like 1; RPS6KA2; ribosomal protein S6 kinase 2; SPARC, secreted protein, acidic,
cysteine-rich; ST AT3 , signal transducer and acti vator of transcription 3; TNF, tumour necrosis
factor- ; TPA, tissue plasminogen activator.

ARHI(DlRAS3)

% of cancers
downregulated or
inactivated
60%

ARLI]

62%

BRCA]

6-8%

BRCA2

3-6%

DAB2 (DOC2)

58-85%

DLECI

73%

OPCML

56-83%

Gene

Mechanism of
downregulation
Imprinting; LOH;
promoter methylation;
transcription
downregulated by
E2FI and E2F4

Function

26 kDa GTPase; inhibits
proliferation and motility;
induces autophagy and
dormancy; upregulates p21;
inhibits cyelin 01, PI3K, RasMa k si
Ilin and STA T3
Promoter methylation ADP ribosylation factor; induces
a 0 tosis
=---..-",
Mutation; LOH
E3 ubiquitin ligase that
participates directly in repair of
DNA DSBs through homologous
recombination; regulates ABL1;
induces p53, androgen receptor,
~_~
oe
~strogen rece tor and MYC
Binds RAD51 during repair of
Mutation; LOH
DNA double strand breaks
Transcription
Binds GRB2, preventing Ras
and MAPK activation; prevents
FOS induction and decreases
ILK activity; contributes to
anoikis; inhibits proliferation;
inhibits anchorage-independent
owth and tumori enici
----~~
Promoter
Inhibits anchorage-dependent
hypennethylation and growth
histone
h oacetylation
-.,....-,,.......,.----..,=
Promoter methylation; GPI-anchored IgLON family
LOH; mutation
member; induces aggregation;

90

PEG3

75%

Imprinting; LOR;
promoter methylation;
transcri tion
Imprinting; LOR;
transcription
downregulated by
EGF and TPA
Promoter methylation;
LOR; mutation

PLAGLl
(LOTl)

39%

PTEN

20%

RASSFJA

60%

Rypermethylation

RPS6KA2

64%

Monoallelic
expressIOn ill ovary;
LOR

SPARe

70-90%

Transcription

TP53

50-70%

Mutation

WWOX

30-49%

LOR; mutation

inhibits proliferation and
tumorigenici
Induces p53-dependent apoptosis

Inhibits proliferation and
tumorigenicity

decreases proliferation,
migration, and survival through
Akt; decreases cyclin D;
Increases 27
Inhibits proliferation and
tumorigenicity; interacts with
Ras inhibiting and
downregulating cyelin D and
signaling through JNK;
stabilizes microtubules; regulates
spindle checkpoint; regulates
C095- and TNF -induced
a 0 tosis
Inhibits growth; induces
apoptosis ; decreases Erk
phosphorylation and cyelin D 1;
Increases 21 and 27
Binds GRB2, preventing Ras
and MAPK activation; prevents
FOS induction and decreases
ILK activity; contributes to
anoikis; inhibits proliferation;
inhibits anchorage-independent
owth and tumori enici
Induces p21 leading to cell cycle
arrest and promotion of DNA
stability; induces apoptosis
Decreases anchorageindependent growth and
tumorigenicity; mouse
homologue required for
a~o~tosis
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